8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549




                                    FORM 8-K




                Current Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934



                                November 17, 2000

                Date of Report (Date of earliest event reported)




                                ADAC LABORATORIES
             (Exact name of registrant as specified in its charter)




         California                       0-9428                 94-1725806
- -------------------------------   ------------------------  --------------------
(State or other jurisdiction of   (Commission File Number)    (I.R.S. Employer
        incorporation)                                       Identification No.)




                                 540 Alder Drive
                           Milpitas, California 95035
                    (Address of principal executive offices)

                                 (408) 321-9100
               (Registrant's telephone number, including area code








ITEM 2.

         On October 24, 2000, ADAC Laboratories, a California corporation
("ADAC") entered into an Agreement and Plan of Merger ("Merger Agreement") by
and among ADAC, ADAC Healthcare Information Systems, Inc., a Texas corporation
and wholly-owned subsidiary of ADAC ("HCIS"), Cerner Corporation, a Delaware
corporation ("Cerner") and Cerner RIS Acquisition Corporation, a Delaware
corporation and wholly-owned subsidiary of Cerner ("Acquisition Sub") pursuant
to which Acquisition Sub will merge with and into HCIS (the "Merger"), as is
more fully described in the Merger Agreement. A copy of the Merger Agreement is
attached hereto as Exhibit 2.1 and is incorporated herein by reference.

         On November 17, 2000, all conditions to closing were satisfied and the
Merger closed. Cerner will pay a total of approximately $6 million cash
consideration for the shares of HCIS, of which approximately $4 million was paid
at closing, $1 million is to be paid on November 17, 2001 and the remaining $1
million is to be paid on November 17, 2002, subject to adjustment. The
consideration amount was determined pursuant to arms-length negogiations.

         HCIS is located in Houston, Texas and provides information and image
management solutions for radiology departments of healthcare facilities. Cerner
designs, develops and supports information systems and content solutions for
health organizations and consumers.

         On October 24, 2000, ADAC and Cerner issued a press release announcing
the signing of the Merger Agreement, a copy of which is attached hereto as
Exhibit 99.1 and is incorporated by reference.

         On November 21, 2000, Cerner issued a press release announcing the
closing of the Merger, a copy of which is attached hereto as Exhibit 99.2 and is
incorporated by reference.

ITEM 7.           FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
                  EXHIBIT C.

                  (a)      Financial statements of Business Acquired.  None.

                  (b)      Pro Forma Financial Information.  To be filed by
                           amendment.

                  (c)      Exhibits. See attached.

                  EXHIBIT NUMBER        DESCRIPTION

                  2.1                   Merger Agreement, dated as of October
                                        24, 2000, by and among ADAC, HCIS,
                                        Cerner and Acquisition Sub

                  99.1                  Press release dated October 24, 2000

                  99.2                  Press release dated November 21, 2000







                                   SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           ADAC LABORATORIES


Dated: December 1, 2000

                                           By: /s/ Andrew Eckert
                                              -------------------------
                                               Andrew Eckert
                                               Chief Executive Officer







                                  EXHIBIT INDEX



                 EXHIBIT NUMBER          DESCRIPTION

                                     
                 2.1                     Merger Agreement, dated October 24, 2000, by and
                                         among ADAC, HCIS, Cerner and Acquisition Sub

                 99.1                    Press release dated October 24, 2000.

                 99.2                    Press release dated November 21, 2000

EX-2.1

                                                                     EXHIBIT 2.1

                          AGREEMENT AND PLAN OF MERGER

          This Agreement and Plan of Merger (the "Agreement") is entered into as
of October 23, 2000 by and between Cerner Corporation, a Delaware corporation
("Buyer"), Cerner RIS Acquisition Corporation, a Delaware corporation and
wholly-owned subsidiary of Buyer ("Merger Sub"), ADAC Laboratories, a California
corporation ("Seller"), and ADAC Healthcare Information Systems, Inc., a Texas
corporation and wholly-owned subsidiary of Seller (the "Company").

                                    RECITALS

          WHEREAS, the Board of Directors of each of Buyer, Merger Sub, Seller
and the Company believe it is in the best interests of each company and its
respective shareholders that Buyer acquire the Company through the statutory
merger of Merger Sub with and into the Company (the "Merger") and, in
furtherance thereof, have approved the Merger.

          WHEREAS, pursuant to the Merger, among other things, all of the issued
and outstanding capital stock of the Company shall be converted into the right
to receive the consideration set forth below.

          NOW, THEREFORE, in consideration of the mutual covenants,
undertakings, representations and warranties set forth herein, the parties agree
as follows:

                                    ARTICLE 1
                                   DEFINITIONS

          For purposes of this Agreement, the terms set forth below shall have
the following meanings:

          1.1       "ACCOUNTS RECEIVABLE" means all accounts receivable, trade
receivables, notes receivable and other receivables, which in any case are
payable as a result of goods sold or services provided, billed for or for which
a revenue has been earned but the amount has not yet been billed, by the Company
in connection with the Business, net of reserves determined in accordance with
the historical practice of the Company.

          1.2       "ACTION" means any action, suit, arbitration, inquiry,
proceeding or investigation by or before any Governmental Authority or
arbitrator.

          1.3       "AFFILIATE" means:

                    1.3.1     with respect to any Person which is a business
entity:

                              (a)       any Person owning or holding, directly
          or indirectly, 10% or more of the equity capital in such business
          entity; or

                              (b)       any Person in which such business entity
          owns or holds, directly or indirectly, 10% or more of the equity
          capital.




                    1.3.2     with respect to any Person which is a trust or
similar entity:

                              (a)       any trustee or other fiduciary of such
          trust or similar entity; or

                              (b)       any direct or indirect beneficiary of
          such trust or similar entity.

                    1.3.3     with respect to any natural Person, any spouse,
parent, child, grandchild grandparent, brother or sister of such Person.

          1.4       "AGREEMENT" means this Agreement, together with the
Schedules and Exhibits hereto.

          1.5       "BASELINE BALANCE SHEET" shall have the meaning set forth in
Section 2.11.

          1.6       "BASELINE BALANCE SHEET DATE" shall have the meaning set
forth in Section 2.11.

          1.7       "BUSINESS" means all business conducted by the Company prior
to the Closing Date.

          1.8       "BUYER" shall have the meaning set forth in the first
paragraph of this Agreement.

          1.9       "BUYER INDEMNITEES" shall have the meaning set forth in
Section 10.1.

          1.10      "BUYER'S KNOWLEDGE" means the actual knowledge of the
officers and directors of Buyer, and the knowledge officers and directors of
Buyer reasonably should have obtained as an officer and/or director of Buyer,
respectively, in carrying out such duties in good faith.

          1.11      "CARDIOLOGY SYSTEMS GROUP" means the assets, liabilities,
obligations, business and goodwill used exclusively in connection with the
business identified by the Company as the "Cardiology Systems Group."

          1.12      "CHARTER DOCUMENT" means the Articles or Certificate of
Incorporation of the Company, Seller, Merger Sub or Buyer, as the case may be,
and any amendment to such document.

          1.13      "CLOSING" means the consummation of the transactions
contemplated hereby, including without limitation, the effectiveness of the
Merger.

          1.14      "CLOSING DATE" shall have the meaning set forth in Section
2.2.


          1.15      "CLOSING DATE BALANCE SHEET" shall have the meaning set
forth in Section 2.11.

          1.16      "CODE" shall mean the Internal Revenue Code of 1986, as
amended, or any successor law, and regulations issued thereunder.

          1.17      "COMPANY EMPLOYEE PLANS" shall have the meaning set forth in
Section 3.19.1.

                                       2


          1.18      "CONSENT" means a consent, approval, authorization, waiver
or notification from any Person, including any Governmental Authority.

          1.19      "CONTRACTS" means all contracts, agreements, undertakings,
instruments, leases, licenses, commitments and arrangements, except Permits.

          1.20      "DAMAGES" means all losses, claims, damages, costs, fines,
penalties, obligations, payments and Liabilities (including those arising out of
any Action), together with all reasonable costs and expenses (including
reasonable outside attorneys' fees and reasonable out-of-pocket expenses)
incurred in connection with any of the foregoing.

          1.21      "DOLLARS" or "$" means lawful currency of the United States.

          1.22      "EMPLOYEE" shall have the meaning set forth in Section
3.18.1.

          1.23      "ENVIRONMENT" means soil, land surface or subsurface strata,
surface waters (including navigable waters, ocean waters, streams, ponds,
drainage basins, and wetlands), groundwaters, drinking water supply, stream
sediments, ambient air (including indoor air), plant and animal life, and any
other environmental medium or natural resource.

          1.24      "ENVIRONMENTAL LAWS" means any Law that requires or relates
to: (i) advising appropriate authorities, employees and the public of intended
or actual releases of pollutants or Hazardous Materials, violations of discharge
limits or other prohibitions and of the commencements of activities that could
have a significant impact on the Environment; (ii) preventing or reducing to
acceptable levels the release of pollutants or hazardous substances or materials
into the Environment; (iii) reducing the quantities, preventing the release, or
minimizing the hazardous characteristics of wastes that are generated; (iv)
assuring that products are designed, formulated, packaged and used so that they
do not present unreasonable risks to human health or the Environment when used
or disposed of; (v) protecting resources, species or ecological amenities; (vi)
reducing to acceptable levels the risks inherent in the transportation of
hazardous substances, pollutants, oil or other potentially harmful substances;
(vii) cleaning up pollutants that have been released, preventing the threat of
release, or paying the costs of such clean up or prevention; or (viii) making
responsible parties pay private parties, or groups of them, for damages done to
their health or the Environment, or permitting self-appointed representatives of
the public interest to recover for injuries done to public assets.

          1.25      "ERISA" means the Employee Retirement Income Security Act of
1974, as amended.

          1.26      "ERISA AFFILIATE" shall have the meaning set forth in
Section 3.19.1.

          1.27      "EXCHANGE ACT" shall mean the Securities Exchange Act of
1934, as amended.

          1.28      "GAAP" means U.S. generally accepted accounting principles
at the time in effect and applied by the Company on a basis consistent with
prior periods.



                                       3


          1.29      "GOVERNMENTAL AUTHORITY" means any U.S. or Canadian federal,
state or local government, any of its subdivisions, agencies, authorities,
commissions, boards or bureaus, any U.S. or Canadian federal, state or local
court or tribunal and any arbitrator.

          1.30      "GUARANTEE" means any guarantee, any indemnification
obligation and any other contingent obligation to purchase, to provide funds for
payment or to supply funds to invest in any Person or otherwise to assure a
creditor against loss.

          1.31      "HAZARDOUS MATERIALS" means any waste or other substance
that is listed, defined, designated, or classified as, or otherwise determined
to be, hazardous, radioactive, or toxic or a pollutant or a contaminant under or
pursuant to any Environmental Law, including any mixture or solution thereof,
and specifically including petroleum and all derivatives thereof or synthetic
substitutes therefor and asbestos or asbestos-containing materials.

          1.32      "INCOME TAX" means any U.S. federal, state, local or foreign
income, alternative minimum, franchise or other similar Tax, duty, governmental
charge or assessment imposed by or on behalf of any Governmental Authority that
is based on or measured by income (including interest and penalties on any of
the foregoing).

          1.33      "INCOME TAX RETURNS" means any Returns with respect to
Income Tax.

          1.34      "INDEMNITEE" shall have the meaning set forth in Section
10.3.1.

          1.35      "INDEPENDENT FIRM" shall have the meaning set forth in
Section 2.11.

          1.36      "INTELLECTUAL PROPERTY ASSETS" shall have the meaning set
forth in Section 3.17.1.

          1.37      "KEY EMPLOYEES" means the Employees of the Company listed on
SCHEDULE 1.37.

          1.38      "LAW" means any U.S. or Canadian federal, state, local or
other statute, rule, regulation or ordinance.

          1.39      "LEASE" means any lease or sublease of real or personal
property.

          1.40      "LEASED PERSONAL PROPERTY" means all right, title and
interest of the Company, as lessee, in and to any personal property leased to
the Company.

          1.41      "LEASED REAL PROPERTY" shall have the meaning set forth in
Section 3.10.

          1.42      "LIABILITY" means any debt, obligation, duty or liability of
any nature (including any undisclosed, unfixed, unliquidated, unsecured,
unmatured, unaccrued, unasserted, contingent, conditional, inchoate, implied,
vicarious, joint, several or secondary liability), regardless of whether such
debt, obligation, duty or liability would be required to be disclosed on a
balance sheet prepared in accordance with GAAP.



                                       4


          1.43      "LIEN" means any lien, mortgage, deed of trust, security
interest, charge, pledge, retention of title agreement, easement, encroachment,
condition, reservation, covenant or other encumbrance affecting title or the
use, benefit or value of the asset in question.

          1.44      "MATERIAL CONTRACTS" shall have the meaning set forth in
Section 3.13.

          1.45      RESERVED.

          1.46      "MATERIAL LEASE" means (i) all Leases relating to the Leased
Real Property, and (ii) a Lease relating to Leased Personal Property involving a
term of more than one year or rental obligations exceeding $10,000 per annum.

          1.47      "MULTIEMPLOYER PLAN" shall have the meaning set forth in
Section 3.19.2.

          1.48      "ORDER" means any order, judgment, injunction, decree,
determination or award of any Governmental Authority or arbitrator.

          1.49      "OTHER LAW" means any Law applicable to the Business of the
Company, other than an Environmental Law or a law relating to (a) Taxes, or (b)
ERISA.

          1.50      "PARTY" means each of Seller and Buyer and "Parties" means
Seller and Buyer, collectively.

          1.51      "PERMIT" means any permit, license, certificate (including a
certificate of occupancy), registration, authorization or approval issued by a
Governmental Authority.

          1.52      "PERMITTED LIENS" means (i) Liens for Taxes that are not yet
due and payable or that are being contested in good faith by appropriate
proceedings and as to which adequate reserves have been established in
accordance with GAAP, consistently applied, (ii) workers', repairmens' and
similar Liens imposed by Law that have been incurred in the ordinary course of
business and consistent with past practice, (iii) Liens and other title defects,
easements, encroachments and encumbrances that do not, individually or in the
aggregate, materially impair the value or continued use of the property (as
currently used) to which they relate, (iv) the rights of others to customer
deposits, and (v) any of the Liens described in the foregoing clauses (i)
through (iv) of this definition incurred in the ordinary course of business and
consistent with past practice, after the date hereof.

          1.53      "PERSON" means any natural person, corporation, partnership,
limited liability company, trust, unincorporated organization or other entity.

          1.54      "PURCHASE PRICE" shall have the meaning set forth in Section
2.9.

          1.55      "REQUIRED CONSENT" shall have the meaning set forth in
Section 3.9.

          1.56      "RETIREMENT PLAN" shall have the meaning set forth in
Section 3.19.2.

          1.57      "RETURNS" shall have the meaning set forth in Section 3.20.


                                       5


          1.58      "SELLER" shall have the meaning set forth in the first
paragraph of this Agreement.

          1.59      "SELLER INDEMNITEES" shall have the meaning set forth in
Section 10.2.

          1.60      "SELLER'S KNOWLEDGE" means the actual knowledge of the
officers and directors of Seller and the knowledge officers and directors of
Seller reasonably should have obtained as an officer and/or director of Seller
carrying out such duties in good faith.

          1.61      "SHARES" shall have the meaning set forth in Section 3.4.

          1.62      "TAX" or "TAXES" means all income, profits, franchise, gross
receipts, capital, sales, use, withholding, value added, ad valorem, transfer,
employment, social security, disability, occupation, property, severance,
production, excise and other taxes, duties and similar governmental charges and
assessments imposed by or on behalf of any Governmental Authority (including
interest and penalties thereon).

          1.63      "TAX LAWS" means the Code and all other Laws relating to
Taxes.

          1.64      "THIRD PARTY CLAIM" shall have the meaning set forth in
Section 10.3.2.

                                    ARTICLE 2
                                   THE MERGER

          2.1       THE MERGER. At the Effective Time (as defined in Section 2.2
below) and subject to and upon the terms and conditions of this Agreement and
the applicable provisions of the Texas Business Corporation Act and the Delaware
General Corporation Law (the "Merger Laws"), Merger Sub shall be merged with and
into the Company, the separate corporate existence of Merger Sub shall cease and
the Company shall continue as the surviving corporation and as a wholly-owned
subsidiary of Buyer. The surviving corporation after the Merger is sometimes
referred to as the "Surviving Corporation."

          2.2       CLOSING.

                    2.2.1     TIME AND PLACE. On the terms and subject to the
conditions of this Agreement, the Closing shall take place at the offices of
the Buyer, located at 2800 Rockcreek Parkway, North Kansas City, Missouri at
2 p.m. local time on the second business day after all of the conditions
precedent set forth in Article 8 below have been satisfied or waived by the
appropriate Party, effective as of 12:01 a.m. on that day, or at such other
time and place as the Parties shall agree upon in writing (the "Closing
Date"). On the Closing Date, the Parties shall cause the Merger to be
consummated by filing Articles of Merger (or like instrument), in
substantially the form attached as EXHIBIT A(1), with the Secretary of State
of the State of Texas (the "Articles of Merger"), and a Certificate of Merger
(or like instrument), in substantially the form attached as EXHIBIT A(2),
with the Secretary of State of the State of Delaware (the "Certificate of
Merger"), in accordance with the applicable provisions of the Merger Laws
(the time of acceptance by the Secretaries of State of the State of Texas and
Delaware of such filing shall be referred to as the "Effective Time").

                                       6


          2.2.2     DELIVERIES BY SELLER. At the Closing, Seller shall deliver
to Buyer the following:

                    (a)       Share certificates representing all of the Shares,
          duly endorsed in blank or accompanied by duly executed stock powers
          duly endorsed in blank;

                    (b)       The recorded Charter Document of the Company,
          recently certified by the Secretary of State of the State of Texas and
          a Certificate of Good Standing of the Company dated within ten
          business days of the Closing Date issued by the Secretary of State of
          the State of Texas;

                    (c)       The recorded Charter Document of Seller, recently
          certified by the Secretary of State of the State of California and a
          Certificate of Good Standing of Seller dated within ten business days
          of the Closing Date issued by the Secretary of State of the State of
          California;

                    (d)       A certificate of the Secretary or Assistant
          Secretary of Seller, dated the Closing Date and substantially in the
          form attached as EXHIBIT B(1), certifying (i) the adoption of
          resolutions of the Board of Directors of Seller authorizing the
          transactions contemplated by this Agreement, (ii) the incumbency and
          signatures of those officers of Seller that executed this Agreement
          and any documents or agreements related to the Closing, and (iii) a
          true and correct copy of the Bylaws of Seller in effect on the Closing
          Date, all in form and substance reasonably satisfactory to Buyer;

                    (e)       A certificate of the Secretary or Assistant
          Secretary of the Company, dated the Closing Date and substantially in
          the form attached as EXHIBIT B(2), certifying (i) the adoption of
          resolutions of the Board of Directors and the sole shareholder of the
          Company authorizing the transactions contemplated by this Agreement,
          (ii) the incumbency and signatures of those officers of the Company
          that executed this Agreement and any documents or agreements related
          to the Closing, and (iii) a true and correct copy of the Bylaws of the
          Company in effect on the Closing Date, all in form and substance
          reasonably satisfactory to Buyer;

                    (f)       A certificate, substantially in the form attached
          as EXHIBIT C(1), of an executive officer of Seller, dated the Closing
          Date, certifying that the conditions to Buyer's obligation to
          consummate the transactions contemplated by this Agreement set forth
          in Sections 8.1.1, 8.1.2 and 8.1.7 have been satisfied;

                    (g)       A written opinion addressed to Buyer from counsel
          for Seller and the Company substantially in the form attached as
          EXHIBIT D(1);

                    (h)       Resignations of each of the members of the Board
          of Directors of the Company; and

                    (i)       Such other documents, instruments and certificates
          as Buyer and Merger Sub may reasonably request in connection with the
          transactions contemplated by this Agreement.



                                       7


                    2.2.3     DELIVERIES BY BUYER. At the Closing, Buyer shall
deliver to Seller the following:

                              (a)       The payment described in Section 2.10.1

          below;

                              (b)       The recorded Charter Document of the
          Merger Sub, recently certified by the Secretary of State of the State
          of Delaware and a Certificate of Good Standing of the Merger Sub dated
          within ten business days of the Closing Date issued by the Secretary
          of State of the State of Delaware;

                              (c)       A certificate of the Secretary or
          Assistant Secretary of Buyer, dated the Closing Date and substantially
          in the form attached as EXHIBIT B(3), certifying the incumbency and
          signatures of those officers of Buyer that executed this Agreement and
          any documents or agreements related to the Closing;

                              (d)       A certificate of the Secretary or
          Assistant Secretary of the Merger Sub, dated the Closing Date and
          substantially in the form attached as EXHIBIT B(4), certifying (i) the
          adoption of resolutions of the Board of Directors and the sole
          stockholder of the Merger Sub authorizing the transactions
          contemplated by this Agreement, (ii) the incumbency and signatures of
          those officers of the Merger Sub that executed this Agreement and any
          documents or agreements related to the Closing, and (iii) a true and
          correct copy of the Bylaws of the Merger Sub in effect on the Closing
          Date, all in form and substance reasonably satisfactory to Seller;

                              (e)       A certificate, substantially in the form
          attached as EXHIBIT C(2), of an executive officer of Buyer, dated the
          Closing Date, certifying that the conditions to Seller's obligations
          to consummate the transactions contemplated by this Agreement set
          forth in Sections 8.2.1 and 8.2.2 have been satisfied;

                              (f)       A written opinion addressed to Seller
          and the Company from counsel for Buyer substantially in the form
          attached as EXHIBIT D(2); and

                              (g)       Such other documents, instruments and
          certificates as Seller and the Company may reasonably request in
          connection with the transactions contemplated by this Agreement.

          2.3       EXPENSES. Seller and Buyer shall each pay their respective
expenses incurred in connection with the negotiation, execution, closing, and
performance of this Agreement. Without limitation of the foregoing:

                    2.3.1     Seller shall be responsible for and pay all stock
transfer taxes payable in connection with the Merger; and

                    2.3.2     Buyer shall be responsible for and pay all sales,
transfer, deed, stamp, notary public and other similar taxes, duties and
transfer fees applicable to the transactions contemplated by this Agreement
(other than stock transfer taxes), including fees to record transfer documents.

                                       8


          2.4       EFFECT OF THE MERGER. At the Effective Time, the effect of
the Merger shall be as provided in the applicable provisions of the Merger Laws.
Without limiting the generality of the foregoing, and subject thereto, at the
Effective Time, except as otherwise agreed to pursuant to the terms of this
Agreement, all the property, rights, privileges, powers and franchises of the
Company and Merger Sub shall vest in the Surviving Corporation, and all debts,
liabilities and duties of the Company and Merger Sub shall become the debts,
liabilities and duties of the Surviving Corporation.

          2.5       ARTICLES OF INCORPORATION AND BYLAWS.

                    2.5.1     Unless otherwise determined by Buyer prior to the
Effective Time, the Articles of Incorporation of the Company, as in effect
immediately prior to the Effective Time, shall be the Articles of Incorporation
of the Surviving Corporation at the Effective Time until thereafter amended in
accordance with the Texas Business Corporation Act and as provided in such
Articles of Incorporation.

                    2.5.2     Unless otherwise determined by Buyer prior to the
Effective Time, the Bylaws of the Company, as in effect immediately prior to the
Effective Time, shall be the Bylaws of the Surviving Corporation at the
Effective Time until thereafter amended in accordance with the Texas Business
Corporation Act and as provided in the Articles of Incorporation of the
Surviving Corporation and such Bylaws.

          2.6       DIRECTORS AND OFFICERS. Unless otherwise determined by
Buyer prior to the Effective Time, the directors of Merger Sub immediately prior
to the Effective Time shall be the directors of the Surviving Corporation
immediately after the Effective Time, to hold the office of a director of the
Surviving Corporation in accordance with the provisions of the Texas Business
Corporation Act and the Articles of Incorporation and Bylaws of the Surviving
Corporation until his or her successors is duly elected and qualified. Unless
otherwise determined by Buyer prior to the Effective Time, the officers of
Merger Sub immediately prior to the Effective Time shall be the officers of the
Surviving Corporation immediately after the Effective Time, to hold office in
accordance with the provisions of the Bylaws of the Surviving Corporation.

          2.7       EFFECT OF MERGER ON THE CAPITAL STOCK OF THE CONSTITUENT
CORPORATIONS.

                    2.7.1     CONVERSION OF COMPANY CAPITAL STOCK. At the
Effective Time, by virtue of the Merger and without any action on the part of
the Merger Sub or the Company, all of the Shares issued and outstanding
immediately prior to the Effective Time (other than any Dissenting Shares (as
defined in Section 2.8 below) and other than shares to be cancelled pursuant to
Section 2.7.2 below), will be canceled and extinguished and converted
automatically into the right to receive the Purchase Price.

                    2.7.2     CANCELLATION OF CERTAIN SHARES OF CAPITAL STOCK OF
THE COMPANY. Any shares of capital stock of the Company that are owned directly
or indirectly by the Company shall be canceled and no portion of the Purchase
Price shall be delivered in exchange therefor.

                                       9


                    2.7.3     ASSUMPTION OF COMPANY OPTIONS TO PURCHASE COMMON
STOCK. No options issued and outstanding under the Company's 1997 Stock Option
Plan (the "Company Option Plan") shall be assumed by Merger Sub or Buyer.

                    2.7.4     CAPITAL STOCK OF MERGER SUB. Each share of Common
Stock of Merger Sub issued and outstanding immediately prior to the Effective
Time shall be converted into and exchanged for one validly issued, fully paid
and nonassessable share of Common Stock of the Surviving Corporation. Each stock
certificate evidencing ownership of any such shares shall continue to evidence
ownership of such shares of capital stock of the Surviving Corporation.

          2.8       DISSENTERS' RIGHTS.

                    (i)       Notwithstanding any other provisions of this
Agreement to the contrary, any shares held by a holder who has exercised and
perfected appraisal rights for such shares in accordance with Section 5.11 of
the Texas Business Corporation Act and who has not effectively withdrawn or lost
such appraisal rights ("Dissenting Shares"), shall not be converted into or
represent a right to receive the consideration set forth in Section 2.9 hereof,
but the holder shall only be entitled to such rights as are provided by the
Texas Business Corporation Act.

                    (ii)      Notwithstanding the provisions of Section 2.8(i)
hereof, if any holder of Dissenting Shares shall effectively withdraw or lose
(through failure to perfect or otherwise) such holder's appraisal rights under
Texas Business Corporation Act, then, as of the later of the Effective Time and
the occurrence of such event, such holder's shares shall automatically be
converted into and represent only the right to receive the consideration
pursuant to 2.9 hereof, without interest thereon, upon surrender of the
certificate(s) representing such shares.

                    (iii)     Seller shall give Buyer (a) prompt notice of any
written demand for appraisal received by it pursuant to the applicable
provisions of Texas Business Corporation Act, and (b) the opportunity to
participate in all negotiations and proceedings with respect to such demands.

          2.9       PURCHASE PRICE. The consideration for the Merger shall be2.9
$5,820,000.00 (the "Purchase Price"), subject to the following conditions and
adjustments:

                    2.9.1     As of the Closing Date, the Company shall have no
indebtedness to third parties (including but not limited to Seller or its
Affiliates), other than (i) payables to vendors and contractors (other than any
payables owed to Seller or its Affiliates), (ii) obligations to employees
incurred in the ordinary course of its business, (iii) lease obligations, and
(iv) intercompany payables to Seller for unreimbursed services and expenses
incurred by Seller on behalf of the Company in the ordinary course of business
(collectively, "Intercompany Trade Payables") (such indebtedness, excluding the
indebtedness set forth in (i) - (iv) above, is referred to as "Financial Debt").
In the event the Company is subject to Financial Debt as of the Closing Date
(other than as provided above), the Purchase Price shall be reduced in the total
amount of such Financial Debt, including any accrued interest and other charges
as of the Closing Date.

                    2.9.2     As of the Closing, the Company shall not have
paid, and shall have no current or future obligation to pay, any amount pursuant
to brokerage commissions and

                                       10


transaction costs or any other fee, commission or other form of compensation to
any financial, legal or other advisor retained to represent the interests of
Seller or the Company in connection with the sale of the Shares or assets of the
Company or similar transaction ("Seller Advisor's Fee"). In the event that, as
of the Closing, the Company has paid or has a current or future obligation to
pay Seller Advisor's Fee, the Purchase Price shall be reduced in the amount of
any such payments or obligations.

          2.10      PAYMENT OF PURCHASE PRICE. The Purchase Price shall be paid
by Buyer to Seller as follows:

                    2.10.1    $3,820,000.00, less the amount of any adjustment
determined in accordance with Section 2.9.1 or Section 2.9.2, shall be paid to
the Seller at Closing by wire transfer of immediately available funds to the
bank account described in wire transfer instructions provided by Seller to Buyer
at least two days prior to Closing;

                    2.10.2    $1,000,000.00, less the amount of any adjustment
determined in accordance with Section 2.11, shall be paid to the Seller on the
first anniversary of the Closing Date, by wire transfer of immediately available
funds to the bank account described in wire transfer instructions previously
provided by Seller to Buyer, or such other instructions provided by Seller to
Buyer at least two days prior to such date.

                    2.10.3    $1,000,000.00, less the amount of any adjustment
determined in accordance with Section 2.11, shall be paid to the Seller on the
second anniversary of the Closing Date, by wire transfer of immediately
available funds to the bank account described in wire transfer instructions
previously provided by Seller to Buyer, or such other instructions provided by
Seller to Buyer at least two days prior to such date.

          2.11      POST-CLOSING ADJUSTMENT. Seller has prepared, in accordance
with GAAP, an unaudited balance sheet of the Company as of October 1, 2000 (the
"Baseline Balance Sheet Date"), which is attached as part of SCHEDULE 3.7.1 (the
"Baseline Balance Sheet"). Seller shall deliver, as soon as available, but in no
event later than the Closing, an audited Baseline Balance Sheet (the "Audited
Baseline Balance Sheet"). Not later than 60 days after the Closing Date, Seller
shall cause its independent auditor, PricewaterhouseCoopers LLP (the
"Independent Firm"), to prepare an audited balance sheet of the Company as of
Closing Date (the "Closing Date Balance Sheet"), which shall be delivered to
Buyer and Seller. The Purchase Price shall be decreased to the extent the total
shareholder's equity reflected in the Baseline Balance Sheet (which, for the
avoidance of doubt, shall be the unaudited Baseline Balance Sheet) exceeds the
total shareholder's equity reflected in the Closing Date Balance Sheet.
Alternatively, the Purchase Price shall be increased to the extent the total
shareholder's equity reflected in the Baseline Balance Sheet (which, for the
avoidance of doubt, shall be the unaudited Baseline Balance Sheet) is less than
that reflected in the Closing Date Balance Sheet. Any decrease in the Purchase
Price to which the Buyer may be entitled pursuant to this Section 2.11 may be
offset against the Buyer's payment obligations under Sections 2.10.2 or 2.10.3
above. Any increase in the Purchase Price to which the Seller may be entitled
pursuant to this Section 2.11 shall be paid to Seller simultaneously with
Buyer's payment obligation under Section 2.10.2 above.

                                       11


          2.12      SECTION 338(h)(10) ELECTION. Seller and Buyer shall timely
make a joint election under Section 338(h)(10) of the Code and any corresponding
elections under U.S. state, local or foreign tax law (collectively the "Section
338(h)(10) Election") with respect to the Merger. Seller will pay any Tax
attributable to the making of the Section 338(h)(10) Election and will indemnify
Buyer and the Company against any adverse consequences arising out of any
failure to pay such Tax. Seller and Buyer shall cooperate with each other to
take all actions necessary and appropriate to effect and preserve a timely
Section 338(h)(10) Election. Seller will prepare the election forms and provide
them to Buyer for Buyer's review at least three days before the Closing Date.
Buyer will execute and return the election forms to Seller at least two calendar
days before the Closing Date. Buyer will file such election forms on or before
the respective due dates for such election forms. Seller and Buyer shall report
the Merger pursuant to this Agreement in a manner consistent with the Section
338(h)(10) Election.

          2.13      ALLOCATION OF PURCHASE PRICE. Seller and Buyer agree that
the Purchase Price and the liabilities of the Company (plus other relevant
items) will be allocated to the assets of the Company for Tax purposes as shown
on the Allocation Schedule which shall be prepared by Buyer and shall be
delivered to Seller within 30 calendar days of the Closing Date. Seller and
Buyer will file all Returns (including amended returns and claims for refund)
and information reports in a manner consistent with such allocation. The Parties
agree that such allocation shall be made in accordance with Section 338(h)(10)
of the Code and any applicable Treasury Regulations.

                                    ARTICLE 3
                    REPRESENTATIONS AND WARRANTIES OF SELLER

          Seller makes the following representations and warranties to Buyer,
except as set forth on the Schedules delivered to Buyer and its counsel:

          3.1       CORPORATE ORGANIZATION. The Company is a corporation duly
organized, validly existing, and in good standing under the laws of the State of
Texas. The Company has all corporate power needed to own or lease and operate
its properties and to conduct its business as now conducted. Seller is a
corporation duly organized, validly existing, and in good standing under the
laws of the State of California. Seller has all corporate power needed to own or
lease and operate its properties and to conduct its business as now conducted.
The Company does not have any subsidiaries and does not hold any equity or other
ownership interest in any other entity.

          3.2       DUE QUALIFICATION. The Company is duly qualified to do
business and is in good standing under the laws of each jurisdiction in which
the nature of its business or properties makes such qualification necessary,
except as would not have a material adverse effect on the Business of the
Company. The list of jurisdictions in which the Company is qualified to do
business is set forth in SCHEDULE 3.2.

          3.3       CORPORATE DOCUMENTATION. Except as set forth on SCHEDULE
3.3, (i) copies of the Charter Documents and the Bylaws that have been delivered
to Buyer are complete and correct, and (ii) the minute books of the Company
shown to Buyer are complete and accurately reflect all proceedings (including
actions taken by written consent) of the shareholders and



                                       12


directors and all committees thereof of the Company in all material respects
since the Company's incorporation.

          3.4       CAPITALIZATION. The entire authorized capital stock of the
Company consists of 15,000,000 shares of Common Stock, par value $0.0001 per
share, and 10,000,000 shares of Preferred Stock, par value $0.0001 per share. Of
the shares of Preferred Stock, 1,500,000 shares have been designated as "Series
A Preferred Stock," of which 1,333,333 shares are issued and outstanding, and
8,500,000 shares have been designated as "Series B Preferred Stock," of which
4,606,539 shares are issued and outstanding (the "Authorized Capital Stock"). As
of the date hereof, there are no shares of Common Stock outstanding. All of the
issued and outstanding shares of Preferred Stock are validly issued and
outstanding and are held by Seller (such issued shares shall be called,
collectively, the "Shares"). The Company has no Treasury Stock. The Shares have
been validly issued, are fully paid, and nonassessable, have not been issued in
violation of any preemptive rights and are owned beneficially and of record by
Seller, free and clear of any Liens. Except as set forth on SCHEDULE 3.4, no
options, warrants or other rights to acquire, sell, or issue shares of capital
stock of the Company are outstanding. None of the Shares were issued in
violation of the Securities Act of 1933, as amended, or any Other Law. The
Shares are, and the Shares to be received by Buyer pursuant to Section 2.7 will
be at the Effective Time, free and clear of all Liens and with no proxies or
restrictions on the voting or other rights pertaining thereto.

          3.5       AUTHORIZATION; EXECUTION AND VALIDITY.

                    (i)       The execution, delivery and performance by Seller
of this Agreement and the consummation by Seller of the transactions
contemplated hereby to be consummated by it have been duly authorized by all
necessary company action. This Agreement has been duly and validly executed and
delivered by Seller, constitutes a valid and binding obligation of Seller and is
enforceable against Seller in accordance with its terms, except to the extent
that the enforcement hereof may be limited by (i) bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in effect
relating to creditors' rights generally, and (ii) general principles of equity
regardless of whether enforceability is considered in a proceeding in equity or
at law.

                    (ii)      The execution, delivery and performance by the
Company of this Agreement and the consummation by the Company of the
transactions contemplated hereby to be consummated by it have been duly
authorized by all necessary company action. This Agreement has been duly and
validly executed and delivered by the Company, constitutes a valid and binding
obligation of the Company and is enforceable against the Company in accordance
with its terms, except to the extent that the enforcement hereof may be limited
by (i) bankruptcy, insolvency, reorganization, moratorium or other similar laws
now or hereafter in effect relating to creditors' rights generally, and (ii)
general principles of equity regardless of whether enforceability is considered
in a proceeding in equity or at law.

          3.6       OFFICERS AND DIRECTORS. SCHEDULE 3.6 sets forth a list of
all of the corporate officers and directors of the Company who are duly elected
and qualified to hold such office on the date hereof.


                                       13


          3.7       FINANCIAL STATEMENTS; ABSENCE OF UNDISCLOSED LIABILITIES.

                    3.7.1     FINANCIAL STATEMENTS. Attached as SCHEDULE 3.7.1
are true and correct copies of the (i) unaudited balance sheet of the Company at
October 1, 2000, and (ii) unaudited statements of income for the fiscal years
ending September 27, 1998, October 3, 1999 and October 1, 2000. Such financial
statements present fairly, in all material respects, the financial condition and
the results of operations of the Company as of the respective dates of and for
the periods referred to in such financial statements, all in accordance with
GAAP consistently applied throughout the periods involved, except as disclosed
in notes to such financial statements.

                    3.7.2     ABSENCE OF UNDISCLOSED LIABILITIES. Except to the
extent (i) fully reflected or reserved against on the Baseline Balance Sheet, or
(ii) disclosed on SCHEDULE 3.7.2, the Company had no Liabilities as of the
Baseline Balance Sheet Date.

          3.8       ABSENCE OF CERTAIN CHANGES. Since the Baseline Balance Sheet
Date, except as set forth on SCHEDULE 3.8, the Company has conducted its
Business in the ordinary course consistent with past practices and there has
been no (i) event or occurrence that has had a material adverse effect on the
Company other than changes or effects arising out of general economic
conditions, (ii) material amendment or termination of any Material Contract,
Material Lease or material Permit relating to the Business, other than in the
ordinary course of business, (iii) material destruction, damage or other loss to
any of the assets of the Company that is not covered by insurance and that is
not reasonably likely to result in a material interruption of the Company's
business, (iv) material sale, lease or other disposition of any of the assets of
the Company, other than the sale of the Cardiology Systems Group and assets
sold, leased or otherwise disposed of in the ordinary course of business and
consistent with past practice, (v) material purchase or lease of any assets of
the Company, other than assets purchased or leased in the ordinary course of
business and consistent with past practice, (vi) material increase in the
compensation payable to any of the Employees, except for increases in the
ordinary course of business and consistent with past practice, or (vii)
agreement or commitment by the Company to take any action described in this
Section 3.8.

          3.9       NO CONFLICT; SELLER CONSENTS. Except as set forth on
SCHEDULE 3.9, the execution, delivery and performance of this Agreement by each
of Seller and the Company will not (i) violate any material Law to which either
Seller or the Company is subject, (ii) violate any Charter Document of Seller or
the Company, (iii) violate any Order to which either Seller or the Company is a
party or by which either Seller or the Company is bound, (iv) require any
Consent from any Person, including any Governmental Authority, except for
actions required to be taken by Buyer and Merger Sub, (v) breach any Material
Contract, Material Lease or material Permit relating to the Business, or (vi)
result in the creation of any Lien on any of the assets of the Company (each
Consent set forth in SCHEDULE 3.9 as a result of clauses (iii), (iv), (v) and
(vi), above, is referred to herein as a "Required Consent").

          3.10      LEASED REAL PROPERTY. The Company owns no real property.
SCHEDULE 3.10 lists all of the real property leased to the Company ("Leased Real
Property"). Except as set forth on SCHEDULE 3.10, all Material Leases of Leased
Real Property are valid and binding and in full force and effect. There has been
no material breach of any such Material Lease by the Company



                                       14


or, to Seller's Knowledge, any other Person, which breach has not been cured or
waived. A true and complete copy of each of the Material Leases, as amended to
date, has been furnished to Buyer. The Company is the lessee or sublessee under
all Material Leases or has succeeded (or will succeed prior to Closing) to the
rights of the lessee under such Material Lease and owns the leasehold interest
created pursuant to such lease free and clear of all Liens except Permitted
Liens. The Company validly occupies such Leased Real Property in accordance with
the terms of such Material Leases free and clear of all Liens except Permitted
Liens.

          3.11      PERSONAL PROPERTY.

                    3.11.1    OWNED PERSONAL PROPERTY. Except as set forth on
SCHEDULE 3.11.1, subject to Permitted Liens, the Company has marketable and
indefeasible title to all personal property owned by the Company or used in the
conduct of the Business, other than (i) property that has been disposed of in
the ordinary course of business, (ii) property that has been disposed of in
transactions disclosed to Buyer prior to the date hereof, which shall include
without limitation the Cardiology Systems Group, and (iii) Leased Personal
Property.

                    3.11.2    LEASED PERSONAL PROPERTY. SCHEDULE 3.11.2 lists
all of the Company's Material Leases of Leased Personal Property used in the
Business. All such Material Leases of Leased Personal Property are valid and
binding and in full force and effect. There has been no material breach of any
such Material Lease by the Company or, to Seller's Knowledge, any other Person,
which breach has not been cured or waived.

          3.12      ACCOUNTS RECEIVABLE. SCHEDULE 3.12 sets forth all Accounts
Receivable of the Company as of the Baseline Balance Sheet Date, and the
approximate aging of such Accounts Receivable. Except as set forth on SCHEDULE
3.12, all Accounts Receivable of the Company reflected on SCHEDULE 3.12 and all
Accounts Receivable of the Company generated after the Baseline Balance Sheet
Date that are reflected in the accounting records of the Company as of the
Closing Date represent or will represent valid obligations arising from sales
actually made or services actually performed or billed for in the ordinary
course of the Business. To Seller's Knowledge, all Accounts Receivable are
current and collectible in the ordinary course of business except to the extent
reflected in the reserve for doubtful accounts in the Baseline Balance Sheet or
in SCHEDULE 3.12. The reserve for doubtful accounts reflected in the Baseline
Balance Sheet has been determined consistent with past practices and in
accordance with GAAP. The Company has good and valid title to the Accounts
Receivable free and clear of all Liens except Permitted Liens.

          3.13      CONTRACTS. SCHEDULE 3.13 lists all written Contracts and
describes in reasonable detail all unwritten Contracts to which the Company is a
party or the assets of the Company are subject, meeting any of the following
descriptions ("Material Contracts"):

                    3.13.1    contracts relating to (i) the suppliers of
components incorporated within the Company's products, (ii) products and
services which the Company purchases, resells or distributes, and (iii) all
other contracts of the Company pursuant to which the Company is obligated to
expend $100,000 or more per year;



                                       15


                    3.13.2    the top 20, based on revenues as of the Baseline
Balance Sheet Date, customer contracts regarding the Company's QuadRIS product,
four of which include the Company's Envoi product;

                    3.13.3    the top ten, based on revenues as of the Baseline
Balance Sheet Date, MARS client support contracts of the Company;

                    3.13.4    the Company's Images and laboratory client support
contracts;

                    3.13.5    contracts relating to the borrowing or lending of
money or the creation of any guarantee or security interest affecting the
Company;

                    3.13.6    contracts entered into by the Company other than
in the ordinary course of its business;

                    3.13.7    contracts that are not terminable by the Company
prior to one year from the date hereof;

                    3.13.8    contracts that limit the freedom of the Company to
compete in any line of business or to conduct business in any geographic
location;

                    3.13.9    pending contracts relating to the purchase, sale
or combination of any business or line of business (by asset transfer, equity
transfer, merger, consolidation or otherwise); and

                    3.13.10   contracts relating to any joint venture,
partnership or other cooperative arrangement with any third party.

Contracts listed or described by Seller in SCHEDULES 3.10, 3.11.2, 3.18.1,
3.18.3, 3.19.1, 3.21 and 3.22 will be deemed to have been listed or described in
SCHEDULE 3.13. All Material Contracts are valid and binding and in full force
and effect. There has been no material breach of any Contract by the Company or,
to Seller's Knowledge, any other Person, which breach has not been cured or
waived. The Company has not been informed that any significant customer, vendor
or supplier of the Company intends to discontinue or substantially alter its
relationship with the Company.

          3.14      LITIGATION; ORDERS. Except as set forth on SCHEDULE 3.14,
there is no Action by any Person or by or before any Governmental Authority that
is pending or, to Seller's Knowledge threatened, by, against or affecting the
Company or any of its assets. Except as set forth on SCHEDULE 3.14, to Seller's
Knowledge, the Company is not subject to any Order.

          3.15      ENVIRONMENTAL LAWS. With respect to the ownership and
operation of the Business: (i) the Company is in compliance in all material
respects with all Environmental Laws; (ii) the Company is not aware of any fact
or circumstance which could result in any environmental liability which could
reasonably be expected to result in a material adverse effect on the Business of
the Company; (iii) as of the Closing, except in compliance with Environmental
Laws in a manner that could not reasonably be expected to subject the Company to
liability, to the Seller's Knowledge, no Hazardous Materials are present on any
Leased Real


                                       16


Property; and (iv) no written notice, notification, demand, request for
information, citation, summons, complaint or Order has been received by, and no
Action is pending, or to Seller's Knowledge, threatened by any Person against
the Company with respect to any Environmental Law.

          3.16      OTHER LAWS. To Seller's Knowledge, the Company has not
failed, in any material respect, to (i) comply with any material Other Law, or
(ii) maintain in effect and comply with any Permit required by any Other Law.
SCHEDULE 3.16 sets forth all material Permits owned or held by the Company. No
action is pending or, to Seller's Knowledge, threatened to revoke or limit any
such Permit which, if adversely determined, would be material to the Business.
All of the Company's Permits are valid and in full force and effect and the
Company is not in default, and no circumstances exist which could cause any
Permit to be revoked, modified or rendered nonrenewable upon payment of the
Permit fee.

          3.17      INTELLECTUAL PROPERTY.

                    3.17.1    INTELLECTUAL PROPERTY ASSETS. The term
"Intellectual Property Assets" means the following, each of which are owned,
used or licensed by the Company, except in connection with the Cardiology
Systems Group and except for those the absence or loss of which would not have a
material adverse effect on the Business of the Company:

                              (a)       fictional business names, trading names,
          registered and unregistered trademarks, service marks, and
          applications therefor as well as the goodwill of the business
          associated therewith (collectively, "Marks");

                              (b)       patents, patent applications, and
          inventions and discoveries that may be patentable (collectively,
          "Patent Rights");

                              (c)       copyrightable works in both published
          works and unpublished works registered and unregistered, including any
          software (collectively, "Copyrights"); and

                              (d)       trade secrets (such as customer
          information, technical and non-technical data, a formula, pattern,
          compilation, program, device, method, technique, drawing, process) and
          other confidential and proprietary information concerning the
          products, processes or services of the Company (collectively, "Trade
          Secrets").

          The Intellectual Property Assets constitute all of the Marks, Patent
Rights, Copyrights and Trade Secrets which are necessary for the conduct of the
Business (other than the Cardiology Systems Group) in the manner conducted by
the Company as of the Baseline Balance Sheet Date.

                    3.17.2    AGREEMENTS. SCHEDULE 3.17.2 contains a complete
and accurate list of all royalty or fee-bearing Contracts involving or relating
to the Intellectual Property Assets to which the Company is licensor, or all
royalty or fee-bearing Contracts involving Marks, Patent Rights, Copyrights or
Trade Secrets of third parties to which the Company is bound as licensee. There
are no outstanding and, to the Seller's Knowledge, no threatened disputes or
disagreements with respect to any such Contracts.

                                       17


                    3.17.3    NO ENCUMBRANCES. Other than as described in that
certain Domestic Subsidiary Security Agreement (Intellectual Property) granted
by the Company in favor of ABN Amro Bank, N.V. ("ABN Amro") and the ABN Amro
guaranty described in Section 8.1.8 below, the Intellectual Property Assets are
held free and clear of all Liens, security interests, charges, encumbrances,
equities, and other adverse claims. All current Employees of the Company and, to
the Seller's Knowledge, all former Employees, have executed written Contracts
with the Company that assign to the Company all rights to any inventions,
improvements, discoveries or information relating to the Business after such
time as such Employees became employed by the Company. No Employee of the
Company has entered into any Contract that restricts or limits in any way the
scope or type of work in which the Employee may be engaged or requires the
Employee to transfer, assign, or disclose information concerning his or her work
to anyone other than the Company.

                    3.17.4    PATENT RIGHTS. Except as set forth in SCHEDULE
3.17.4, the Company does not own or license any Patent Rights and has not filed
any applications for a patent. To the Seller's Knowledge, none of the products
manufactured and sold or services rendered, nor any process or know-how used, by
the Company infringes or is alleged to infringe any patent or other proprietary
right of any other Person.

                    3.17.5    TRADEMARKS.

                              (a)       SCHEDULE 3.17.5 contains a complete and
          accurate list and summary description of all Marks owned by the
          Company, including the dates of first use of each such Mark and
          samples evidencing the manner in which the Mark has been used. The
          Company is the owner of all right, title, and interest in and to each
          of the Marks set forth in SCHEDULE 3.17.5 free and clear of all Liens,
          security interests, charges, encumbrances, equities and other adverse
          claims, except to the extent the absence or loss of such Marks would
          not have a material adverse effect on the Business.

                              (b)       To the Seller's Knowledge, no Mark set
          forth in SCHEDULE 3.17.5 has been or is now involved in any
          opposition, invalidation, or cancellation and no such action is
          threatened with respect to any of such Marks.

                              (c)       To Seller's Knowledge, there is no
          potentially interfering trademark or trademark application of any
          third party with respect to such Marks.

                              (d)       To the Seller's Knowledge, no such Mark
          is infringed or has been challenged or threatened in any way. To
          Seller's Knowledge, none of the Marks set forth in SCHEDULE 3.17.5
          used by the Company infringes or is alleged to infringe any trade
          name, trademark or service mark of any third party.

                              (e)       All products and materials containing
          such Marks bear the proper federal registration notice where permitted
          by law.

                    3.17.6    COPYRIGHTS. To the Seller's Knowledge, none of the
subject matter of any of the Company's Copyrights infringes or is alleged to
infringe any copyright of any third party or is a derivative work based on the
work of a third party. Except as set forth in SCHEDULE 3.17.6, the Company is
the owner of all right, title, and interest in and to each of such Copyrights



                                       18


free and clear of all Liens, security interests, charges, encumbrances, equities
and other adverse claims, except to the extent the absence or loss of such
Copyrights would not have a material adverse effect on the Business.

                    3.17.7    TRADE SECRETS.

                              (a)       With respect to each Company Trade
          Secret, the documentation relating to such Trade Secret is current,
          accurate, and sufficient in detail and content to identify and explain
          it and to allow its full and proper use without reliance on the
          knowledge or memory of any individual.

                              (b)       Seller has taken all reasonable
          precautions to protect the secrecy, confidentiality, and value of such
          Trade Secrets. The Company has good title and an absolute right to use
          such Trade Secrets, except to the extent the absence or loss of such
          Trade Secrets would not have a material adverse effect on the
          Business. Such Trade Secrets are not part of the public knowledge or
          literature, and, to Seller's Knowledge, have not been used, divulged,
          or appropriated either for the benefit of any Person or to the
          detriment of Seller. To Seller's Knowledge, no adverse claim to any
          such Trade Secret has been asserted. To Seller's Knowledge, no such
          Trade Secret is subject to any adverse claim, has been challenged or
          threatened in any way or infringes any proprietary right of any other
          Person.

          3.18      EMPLOYEES; EMPLOYMENT AGREEMENTS AND POLICIES.

                    3.18.1    SCHEDULE 3.18.1 sets forth for each employee of
the Company ("Employee"), the Employee's (i) date of employment, (ii) job title
or position, (iii) base salary on an annualized basis, (iv) work location, (v)
eligibility, if any, for any bonus payment, and (vi) eligibility for or receipt
of options to purchase capital stock of the Company or Seller. Seller and the
Company shall use commercially reasonable efforts to continue the employment of
said Employees with the Company until the Closing. To Seller's Knowledge, no
director, officer or Key Employee intends to terminate his employment with the
Company prior to Closing.

                    3.18.2    None of the Employees is subject to a collective
bargaining or other labor union agreement. No material work stoppage or material
labor dispute against the Company in connection with the Business is pending or,
to Seller's Knowledge, threatened and, to Seller's Knowledge, there is no
related organizational activity by any Employees. As of the date hereof, the
Company has not received any written notice of any unfair labor practice in
connection with the Business, and, to Seller's Knowledge, no such complaints are
pending before the National Labor Relations Board or other similar Governmental
Authority.

                    3.18.3    SCHEDULE 3.18.3 sets forth a list (in the case of
written documents) or description (in the case of unwritten material) of any of
the following with respect to which the Company has or may have any existing or
future obligation (the "Employment Obligations") to any past or present
Employee, consultant, individual independent contractor, director, officer or
person engaged in any similar capacity:

                              (a)       Contracts between the Company and any
          such Employee, consultant, individual independent contractor,
          director, officer or person; or



                                       19


                              (b)       Policies, plans, terms, conditions or
          practices of the Company relating to any aspect of the Company's
          relations with Employees generally, or any individual or class of
          Employees, consultants, individual independent contractors, directors,
          officers or persons.

                    3.18.4    No Employee or director of the Company is a party
to, or is otherwise bound by, any agreement or arrangement, including any
confidentiality, noncompetition, or proprietary rights agreement, between such
Employee or director and any other Person ("Proprietary Rights Agreement") that
in any way adversely affects or will affect the ability of the Company to
conduct its Business, including any Proprietary Rights Agreement with the
Company by any such Employee or director.

          3.19      BENEFIT PLANS.

                    3.19.1    SCHEDULE 3.19.1 contains a correct and complete
list identifying each material "employee benefit plan," as defined in Section
3(3) of ERISA, each employment, severance or similar contract, plan, arrangement
or policy and each other plan or arrangement (written or oral) providing for
compensation, bonuses, profit-sharing, stock option or other stock related
rights or other forms of incentive or deferred compensation, vacation benefits,
insurance coverage (including any self-insured arrangements), health or medical
benefits, disability benefits, workers' compensation, supplemental unemployment
benefits, severance benefits and post-employment or retirement benefits
(including compensation, pension, health, medical or life insurance benefits)
that is maintained, administered or contributed to by the Company or any of its
ERISA Affiliates and covers any employee or former employee of the Company.
Copies of such plans (and, if applicable, related trust agreements) and all
amendments thereto and written interpretations will be made available upon
request to Buyer together with the most recent annual report (Form 5500
including, if applicable, Schedule B thereto), the most recent summary plan
description and material employee communications prepared in connection with any
such plan. Such plans are referred to collectively herein as the "Company
Employee Plans." For purposes of this Section 3.19, "ERISA Affiliate" of any
Person means any other Person which, together with such Person, would be treated
as a single employer under Section 414 of the Code.

                    3.19.2    No Company Employee Plan is now or at any time has
been subject to Part 3, Subtitle B of Title I of ERISA or Title IV of ERISA. At
no time has the Company or any of its ERISA Affiliates contributed to, or been
required to contribute to, any "multiemployer plan," as defined in Section 3(37)
of ERISA (a "Multiemployer Plan"), or any other plan subject to Title IV of
ERISA (a "Retirement Plan"), and neither the Company nor any of its ERISA
Affiliates has, or ever has had, any material liability relating to the
withdrawal or partial withdrawal from a Multiemployer Plan. To the Seller's
Knowledge, no condition exists and no event has occurred that would be
reasonably likely to constitute grounds for termination of any Company Employee
Plan that is a Retirement Plan or, with respect to any Company Employee Plan
that is a Multiemployer Plan, presents a material risk of a complete or partial
withdrawal under Title IV of ERISA and neither the Company nor any of its ERISA
Affiliates has incurred any liability under Title IV of ERISA arising in
connection with the termination of, or complete or partial withdrawal from, any
plan covered or previously covered by Title IV of ERISA that would be reasonably
likely to have a material adverse effect on the Company. To the Seller's
Knowledge, nothing has been done or omitted to be done and no transaction or
holding of any



                                       20


asset under or in connection with any Company Employee Plan has occurred that
will make the Company, or any officer or director of the Company, subject to any
liability under Title I of ERISA or liable for any tax pursuant to Section 4975
of the Code (assuming the taxable period of any such transaction expired as of
the date hereof) that would be reasonably likely to have a material adverse
effect on the Company.

                    3.19.3    To the Seller's Knowledge, each Company Employee
Plan that is intended to be qualified under Section 401(a) of the Code now
meets, and at all times since its inception have met, the requirements for such
qualification other than such requirements for which a remedial amendment period
has not expired, and each trust forming a part thereof is now, and at all times
since its inception has been, exempt from tax pursuant to Section 501(a) of the
Code. Each such plan has received a determination letter from the Internal
Revenue Service to the effect that such plan is qualified and its related trust
is exempt from federal income taxes. The Company has furnished, or will make
available upon request, to Buyer copies of the most recent Internal Revenue
Service determination letters with respect to each such Company Employee Plan.
To the Seller's Knowledge, each Company Employee Plan has been maintained and
administered in substantial compliance with its terms and with the requirements
prescribed by any and all statutes, orders, rules and regulations, including but
not limited to ERISA and the Code, which are applicable to such Company Employee
Plan; provided, however, that in any case in which any Company Employee Plan is
currently required to comply with a provision of ERISA or the Code, but has not
yet been amended to reflect such provision under the current remedial amendment
period, such plan has been maintained and administered in accordance with the
provision, and any case in which any Company Employee Plan has been submitted to
the Walk-in Closing Agreement Program of the Internal Revenue Service's Employee
Plans Compliance Resolution System, as set forth in Revenue Procedure 98-22 and
2000-16. To the Seller's Knowledge, all material reports, returns and similar
documents with respect to each Company Employee Plan required to be filed with
any governmental agency or distributed to any Company Employee Plan participant
have been duly timely filed and distributed.

                    3.19.4    There is no contract, agreement, plan or
arrangement that, as a result of the transactions contemplated by this
Agreement, would be reasonably likely to obligate the Company to make any
payment of any amount that would not be deductible pursuant to the terms of
Section 162(m) or Section 280G of the Code.

                    3.19.5    Except as disclosed in writing to the Buyer prior
to the date hereof, there has been no amendment to, written interpretation or
announcement (whether or not written) relating to, or change in employee
participation or coverage under, any Company Employee Plan that would increase
materially the expense of maintaining such Company Employee Plan above the level
of the expense incurred in respect thereof for the fiscal year ended on the
Baseline Balance Sheet Date.

                    3.19.6    No Company Employee Plan promises or provides
post-retirement medical, life insurance or other benefits due now or in the
future to current, former or retired employees of the Company.

          3.20      TAXES. All federal, state, local and foreign tax returns,
reports, declarations and forms relating to the Company or any combined,
consolidated, affiliated or unitary tax group of



                                       21


which the Company is or has been a member that were required to be filed prior
to the date hereof ("Returns") have been accurately prepared in all material
respects and timely filed. All Taxes that have become due for the periods
covered by the Returns and all deficiencies and assessments for any amount of
Taxes that are or would become payable by the Company or chargeable as a Lien
upon any of the Company's assets have been duly and timely paid. Except as set
forth on SCHEDULE 3.20, the Company is not the beneficiary of any extension of
time within which to file any Return. The Company has not made any material
payments, is not obligated to make any material payments and is not a party to
any agreement that under certain circumstances could obligate it to make any
material payments that will not be deductible under Section 280(G) of the Code.

          3.21      INSURANCE. SCHEDULE 3.21 contains a correct and complete
list of all insurance policies of the Company concerning its Business and
property. These policies are in the amounts set forth in SCHEDULE 3.21. The
Company has maintained and now maintains: (i) insurance on all assets and
business of a type customarily insured, covering property damage and loss of
income by fire or other casualty; and (ii) adequate insurance protection against
all liabilities, claims and risks against which it is customary to insure.
Seller is not in default with respect to payment of premiums on any such policy.
Except as set forth in SCHEDULE 3.21, no claim is pending under any such
policies. The Employee Benefits Liability Policy and the Errors and Omission
Policy maintained by Seller are the only claims made coverage policies. At
Buyer's request, Seller will cooperate with Buyer in securing tail coverage with
respect to such policies (such coverage to be at Buyer's expense).

          3.22      AFFILIATE AGREEMENTS. SCHEDULE 3.22 lists each Contract
between the Company and (i) Seller, (ii) any Affiliate of the Company, or (iii)
any Affiliate of Seller which is currently in effect.

          3.23      BROKERS. Except as set forth in SCHEDULE 3.23, no person is
or will become entitled to receive any brokerage or finder's fee, advisory fee
or other similar payment for the transactions contemplated by this Agreement by
virtue of having been engaged by or acted on behalf of the Company or Seller.

          3.24      CONDITION OF ASSETS. The buildings, plants, structures and
equipment utilized by the Company are structurally sound, in good operating
condition and repair, and are adequate for the uses to which they are being put,
and, to Seller's Knowledge, none of such buildings, plants, structures or
equipment is in need of maintenance or repairs except for ordinary, routine
maintenance and repairs that are not material in nature or cost.

          3.25      DEFERRED REVENUE. SCHEDULE 3.25 is a complete and accurate
list for each significant customer of the Company (as set forth on SCHEDULE 3.13
above) of the deferred revenue of the Company for each such customer, as of the
Baseline Balance Sheet Date.

          3.26      BANK ACCOUNTS AND POWERS OF ATTORNEY. SCHEDULE 3.26 sets
forth each bank, savings institution and other financial institution with which
the Company has an account or safe deposit box and the names of all persons
authorized to draw thereon or to have access thereto. Except as disclosed on
SCHEDULE 3.26, the Company has not given any revocable or irrevocable


                                       22


powers of attorney or similar grant of authority to any Person relating to the
Company for any purpose whatsoever.

          3.27      BOOKS AND RECORDS. Except as set forth on SCHEDULE 3.27, all
books of account, minute books and other records relating to the ownership and
operation of the Company are complete and correct and have been maintained in
accordance with sound business practices. At the Closing, all of those books and
records will be in the possession of the Company.

          3.28      CERTAIN BUSINESS PRACTICES. Neither the Company, nor to
Seller's Knowledge, any director, officer, agent or employee of the Company, has
(a) used any funds for unlawful contributions, gifts, entertainment or other
unlawful expenses relating to political activity, (b) made any unlawful payment
to foreign or domestic government officials or employees or to foreign or
domestic political parties or campaigns or violated any provision of the Foreign
Corrupt Practices Act of 1977, as amended (assuming for purposes of this Section
3.28 that the Company is subject to Section 30A of the Exchange Act), or (c)
made any other unlawful payment.

          3.29      REPRESENTATIONS AND WARRANTIES NOT MISLEADING. No
representation or warranty of Seller contained in this Agreement omits to state
any material fact necessary to make the statements made herein or therein, in
light of the circumstances under which they were made, not misleading.

                                    ARTICLE 4
                     REPRESENTATIONS AND WARRANTIES OF BUYER

         Buyer makes the following representations and warranties to Seller:

          4.1       ORGANIZATION; POWER AND AUTHORITY. Buyer is a corporation
duly organized, validly existing and in good standing under the laws of
Delaware. Buyer has all corporate power needed to execute, deliver and perform
its obligations under this Agreement and to consummate the transactions
contemplated hereby to be consummated by it. Merger Sub is a corporation duly
organized, validly existing and in good standing under the laws of Delaware.
Merger Sub has all corporate power needed to execute, deliver and perform its
obligations under this Agreement and to consummate the transactions contemplated
hereby to be consummated by it.

          4.2       AUTHORIZATION; EXECUTION AND VALIDITY.

                    (i)       The execution, delivery and performance by Buyer
of this Agreement and the consummation by Buyer of the transactions contemplated
hereby to be consummated by it have been duly authorized by all necessary
company action. This Agreement has been duly and validly executed and delivered
by Buyer, constitutes a valid and binding obligation of Buyer and is enforceable
against Buyer in accordance with its terms, except to the extent that the
enforcement hereof may be limited by (i) bankruptcy, insolvency, reorganization,
moratorium or other similar laws now or hereafter in effect relating to
creditors' rights generally, and (ii) general principles of equity regardless of
whether enforceability is considered in a proceeding in equity or at law.


                                       23


                    (ii)      The execution, delivery and performance by Merger
Sub of this Agreement and the consummation by Merger Sub of the transactions
contemplated hereby to be consummated by it have been duly authorized by all
necessary company action. This Agreement has been duly and validly executed and
delivered by Merger Sub, constitutes a valid and binding obligation of Merger
Sub and is enforceable against Merger Sub in accordance with its terms, except
to the extent that the enforcement hereof may be limited by (i) bankruptcy,
insolvency, reorganization, moratorium or other similar laws now or hereafter in
effect relating to creditors' rights generally, and (ii) general principles of
equity regardless of whether enforceability is considered in a proceeding in
equity or at law.

          4.3       NO CONFLICT; BUYER CONSENTS. The execution, delivery and
performance by each of Buyer and Merger Sub of this Agreement will not (i)
violate any Law to which Buyer or Merger Sub is subject, (ii) violate any
Charter Document of Buyer or Merger Sub, (iii) violate any Order to which Buyer
or Merger Sub is a party or by which it is bound, (iv) require any Consent from
any Person, including any Governmental Authority, other than the consent and
approval of the U.S. Federal Trade Commission ("FTC") and U.S. Department of
Justice ("DOJ") to the filing made by the Parties pursuant to the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act")
(as described in Section 7.6 below) and actions to be taken by Seller and the
Company, or (v) breach any material Contract to which Buyer or Merger Sub is a
party or by which it is bound.

          4.4       LITIGATION; ORDERS. There is no Action by any Person or by
or before any Governmental Authority that is pending or, to Buyer's Knowledge,
threatened by against or affecting Buyer or any of its properties, assets,
operations or business which would, if adversely determined, have a material
adverse effect on Buyer's ability to consummate the transactions contemplated by
this Agreement, nor is Buyer subject to any Order which would have any such
effect.

          4.5       BROKERS. No Person is or will become entitled to receive any
brokerage or finder's fee, advisory fee or other similar payment for the
transactions contemplated by this Agreement by virtue of having been engaged by
or acted on behalf of Buyer.

                                    ARTICLE 5
                       COVENANTS OF SELLER AND THE COMPANY

          5.1       COOPERATION BY SELLER AND THE COMPANY. From the date hereof
through the Closing Date, Seller shall, and Seller shall cause the Company to,
use all commercially reasonable efforts to take all actions and to do all things
necessary or advisable to consummate the transactions contemplated by this
Agreement and to cooperate with Buyer in connection with the foregoing,
including using commercially reasonable efforts to obtain all of the Required
Consents; provided, however, that Seller and the Company shall not be required
to incur unreasonable expense in connection with their obligations under this
Section 5.1. Unless required for consummation of the transactions contemplated
by this Agreement, Seller and the Company shall have no obligation to amend, or
cause to be amended, any Contract, to change, or cause to be changed, any
Permit, or to make, or cause to be made, any payment to obtain any Required
Consent.



                                       24


          5.2       PRE-CLOSING ACCESS TO INFORMATION. From the date hereof
through the Closing Date, Seller and the Company shall (i) afford to Buyer, its
accountants and its counsel access, in a reasonable manner, upon reasonable
notice and at reasonable times, full and free access to each of the Company's
personnel, properties, contracts, books and records, and other reasonable
documents and data, and the Independent Firm, (ii) furnish Buyer, its
accountants and its counsel with copies of all such contracts, books and
records, and other existing documents and data as Buyer may reasonably request,
and (iii) furnish Buyer, its accountants and its counsel with such additional
financial, operating and other data and information as Buyer may reasonably
request.

          5.3       CONDUCT OF BUSINESS. From the date hereof through the
Closing Date, except as set forth on SCHEDULE 5.3 and except for the sale of the
Cardiology Systems Group, the Company shall, and Seller shall cause the Company
to, in connection with the conduct of the Business, use commercially reasonable
efforts to: (i) preserve substantially its relationships with suppliers,
customers and Employees; (ii) maintain substantially the same amounts and kinds,
in the aggregate, of existing insurance coverage; (iii) perform its obligations
under the Material Contracts and material Permits in all material respects; (iv)
comply with all applicable Laws in all material respects; and (v) carry on the
Business in the ordinary course and consistent with past practice. The Company
shall not, and Seller shall cause the Company to not, in connection with the
conduct of the Business, without the prior written consent of Buyer, which shall
not be unreasonably withheld:

                    5.3.1     incur or guarantee any debt relating to the
Business, except accounts payable incurred in the ordinary course of business
and consistent with past practice;

                    5.3.2     sell, assign or transfer, or permit the creation
of any Lien on, any of the assets of the Company, except for the sale of the
Cardiology Systems Group and any such assets disposed of in the ordinary course
of business and consistent with past practice;

                    5.3.3     enter into any Material Contract or Material Lease
relating to the Business outside the ordinary course of business and consistent
with past practice;

                    5.3.4     amend or terminate any Material Contract, Material
Lease or material Permit relating to the Business in a manner that is not in the
ordinary course of business and consistent with past practice;

                    5.3.5     except for customary merit, cost-of-living and
promotional increases to Employees in the ordinary course of business and
consistent with past practice, increase the rate of compensation or bonus
eligibility for any Employee;

                    5.3.6     pay any dividend or distribution in cash or any
other form to, on behalf of, at the direction of, or for the benefit of, Seller;

                    5.3.7     waive any material right, forgive any material
debt (other than intercompany debt) or release any material claim relating to
the Business, except in the ordinary course of business and consistent with past
practice;

                                       25


                    5.3.8     accelerate or delay the sale of services or
equipment constituting the conduct of the Business or the collection of accounts
receivable of the Company in a manner that is not in the ordinary course of
business and consistent with past practice;

                    5.3.9     take any action that would cause or result in, or
that would reasonably be expected to, cause or result in (i) any of the
representations or warranties set forth in this Agreement not to be true and
correct as of the Closing Date, or (ii) the nonperformance in any material
respect of Seller's covenants set forth in this Agreement; or

                    5.3.10    agree to take any of the actions described in
Sections 5.3.1 through 5.3.9.

          5.4       FURTHER ASSURANCES. Subject to the other terms and
conditions of this Agreement, at any time and from time to time, whether before
or after the Closing, Seller and the Company shall execute and deliver all
instruments and documents and take all other action that Buyer may reasonably
request to consummate or to evidence the consummation of the transactions
contemplated by this Agreement; provided, however, that Seller and the Company
shall not be required to incur unreasonable expense in connection with its
obligation under this Section 5.4.

          5.5       COOPERATION. Prior to the Closing, Seller and the Company
shall provide commercially reasonable cooperation to Buyer and shall take all
actions that are commercially reasonable and requested by Buyer to ensure a
smooth transition of the ownership of the Company from Seller to Buyer.

          5.6       SUPPLEMENTS TO SCHEDULES. If any event occurs or condition
changes that causes any of its representations or warranties in this Agreement
to be inaccurate, Seller shall notify Buyer thereof in writing. Seller may
supplement the Schedules to account for any such event or change. If Seller
gives written notice to Buyer of any proposed supplement to the Schedules and
Buyer fails to deliver a written objection to such proposed supplement within
two business days of Seller's notice, Buyer shall be deemed to have consented to
such proposed supplement.

          5.7       NOTICE OF BREACH. If at any time on or before the Closing
Date, Seller obtains any knowledge (whether through investigation or otherwise)
of any fact, condition or event constituting a material breach of any
representation or warranty of Seller set forth herein or any document referred
to herein, then Seller shall immediately upon obtaining such knowledge inform
Buyer thereof and of such breach. Buyer shall have two business days to waive
such breach in writing or terminate the Agreement in accordance with Section
9.1.1 below, after such time Seller's notice shall be deemed to have qualified
the representations and warranties of Seller contained in Article 3 above, to
have amended the Schedules delivered pursuant hereto, and to have cured any
misrepresentation or breach of warranty that otherwise might have existed
hereunder.

          5.8       EXCLUSIVE DEALING. From the date hereof until the earlier of
(i) the termination of the Agreement pursuant to Article 9 hereof, or (ii) the
Closing Date, Seller and Company shall not, and the Seller and Company shall not
authorize or permit any of the officers, directors or



                                       26


employees of Seller, the Company or any investment banker, financial advisor,
attorney, accountant or other representative retained by Seller or the Company
to, initiate, solicit, negotiate or encourage (including by way of furnishing
information), or take any other action to facilitate or entertain, any inquiries
or the making of any proposal that constitutes, or may reasonably be expected to
lead to, any proposal or offer to acquire all or any part of the Business of the
Company, or all or any part of the Shares or other equity security of the
Company, whether by merger, consolidation, purchase of assets or capital stock,
exchange offer or other similar business combination, whether for cash,
securities or any other consideration or combination thereof (any such
transaction being referred to herein as an "Other Acquisition Transaction"), or
agree to endorse or recommend any such Other Acquisition Transaction; provided,
however, that Seller and the Company, and their directors and officers, will
remain free to participate in any discussions or negotiations regarding, furnish
any information with respect to, assist or participate in, or facilitate in any
manner any effort or attempt by any Person to do or seek any of the foregoing to
the extent their fiduciary duties may require such action. Seller shall provide
Buyer notice of any such participation or furnishing of information. It shall
not be a violation of this Section 5.8 for Seller or the Company to inform a
Person making an unsolicited offer that Seller or the Company, as the case may
be, cannot then discuss any such proposal.

                                    ARTICLE 6
                               COVENANTS OF BUYER

          6.1       COOPERATION BY BUYER. From the date hereof through the
Closing Date, Buyer and Merger Sub shall use commercially reasonable efforts to
take all actions and to do all things necessary or advisable to consummate the
transactions contemplated by this Agreement and to cooperate with Seller in
connection with the foregoing, including using commercially reasonable efforts
to obtain all of the Required Consents; provided, however, that Buyer and Merger
Sub shall not be required to incur unreasonable expense in connection with their
obligation under this Section 6.1.

          6.2       FURTHER ASSURANCES. Subject to the other terms and
conditions of this Agreement, at any time and from time to time, whether before
or after the Closing, Buyer and Merger Sub shall execute and deliver all
instruments and documents and take all other action that Seller may reasonably
request to consummate or to evidence the consummation of the transactions
contemplated by this Agreement; provided, however, that Buyer and Merger Sub
shall not be required to incur unreasonable expense in connection with their
obligation under this Section 6.2.

          6.3       NOTICE OF BREACH. If at any time on or before the Closing
Date, Buyer obtains any knowledge (whether through investigation or otherwise)
of any fact, condition or event constituting a breach of any representation or
warranty of Seller set forth herein or any document referred to herein, then
Buyer shall immediately upon obtaining such knowledge inform Seller thereof and
of such breach.

          6.4       INTERCOMPANY TRADE PAYABLE. Within 30 calendar days of the
Closing Date, Buyer, or the Surviving Corporation, shall pay to Seller the
balance outstanding, as of the Closing Date, of the Intercompany Trade Payable.

                                       27


          6.5       USE OF NAME. Buyer and the Surviving Corporation each agree
that, from and after the Closing Date, it will not use in any manner whatsoever
the name "ADAC" without the prior written consent of Seller; provided, however,
that, until June 30, 2001, Buyer may state, whether in marketing materials or
otherwise, that the Company has been acquired by Buyer pursuant to the Merger
and that the Company is "formerly known as" ADAC Healthcare Information Systems,
Inc. After such period, any use of the name "ADAC" by Buyer may not be made
without the prior written consent of Seller, which shall not be unreasonably
withheld.

                                    ARTICLE 7
                              ADDITIONAL AGREEMENTS

          7.1       GOVERNMENTAL MATTERS.

                    7.1.1     GOVERNMENTAL APPROVALS. Each of Buyer, Seller, the
Company and Merger Sub shall comply with any other Laws which are applicable to
any of the transactions contemplated hereby and pursuant to which government
notification or approval of such transaction is necessary, including without
limitation any notifications or filings under the HSR Act. Such parties shall
cooperate with one another in providing any information about the Company or the
Merger Sub which is required for this purpose and in promptly filing, separately
or jointly, any applications for such government notification or approval. Such
parties shall use commercially reasonable efforts to resolve such objections, if
any, as may be asserted by any Governmental Authority with respect to the
transactions contemplated hereby.

                    7.1.2     NO REQUIRED DISPOSITIONS OR OTHER ADVERSE ACTIONS.
Notwithstanding any other provision of this Agreement to the contrary, neither
Party nor their respective Affiliates shall be obligated, in order to obtain any
Permit or other approval by any Governmental Authority that is necessary to
consummate the transactions contemplated hereby, to (i) hold, separate, sell or
otherwise dispose or make reductions in the scope or use of their respective
businesses, assets or properties, (ii) materially prejudice the benefits to be
received from the transactions contemplated hereby, or (iii) take any action or
refrain from taking any action that may have a material adverse effect on their
respective business, assets, results of operations or financial condition.

          7.2       TAX INFORMATION AND ASSISTANCE. The Parties shall provide
each other with such commercially reasonable assistance as may be requested by
them in connection with the preparation of any Tax Return, any Tax audit or
other examination by any Governmental Authority, or any judicial or
administrative proceedings related to liability for Taxes. The Parties shall
retain and provide each other upon written request with records or information
which may be relevant to such preparation, audit, examination, proceeding or
determination. Such assistance shall include making employees available on a
mutually convenient basis to provide and explain such records and information
and shall include providing copies of any relevant Tax Returns and supporting
work schedules. The Party requesting assistance hereunder shall reimburse the
other for reasonable out-of-pocket expenses incurred in providing such
assistance.



                                       28



          7.3       BOOKS AND RECORDS.

                    7.3.1     ACCESS. For a two year period ending on the second
anniversary of the Closing, each Party shall provide the other Party with
commercially reasonable access during normal business hours to its books and
records relating to the Company (other than books and records protected by the
attorney-client privilege) to the extent that they relate to the condition or
operation of the Business prior to the Closing and are requested by such Party
to prepare its Returns, to respond to Third Party Claims or for any other
legitimate purpose specified in writing. Each Party shall have the right, at its
own expense, to make copies of any such books and records.

                    7.3.2     CONFIDENTIALITY. Each Party may take such action
which it deems to be commercially reasonable to separate or redact information
unrelated to the Business from documents and other materials requested and made
available pursuant to this Section 7.3 and may condition the other Party's
access to documents and other materials that it deems confidential to the
execution and delivery of an agreement by the other Party not to disclose or
misuse such information.

                    7.3.3     ASSISTANCE. Each Party shall, upon receipt of a
commercially reasonable request in writing and at the requesting Party's
expense, make personnel reasonably available to assist in locating and obtaining
any books and records relating to the Company to the extent that they relate to
the condition or operation of the Business prior to the Closing and make
personnel reasonably available whose assistance, participation or testimony is
reasonably required in anticipation of, preparation for or the prosecution or
defense of any Third Party Claim in which the other Party does not have any
adverse interest.

          7.4       COVENANT NOT TO COMPETE.

                    7.4.1     As a material inducement to enter into this
Agreement, Seller agrees that, for a period of five years after the Closing
Date, Seller will not, directly or indirectly, anywhere within North America,
(i) own, manage, operate or control, either directly or indirectly, any business
which is competitive with the business of radiology information systems,
laboratory information systems, image management workflow engine and PACS (the
"HCIS Business"), or divert, or attempt to divert, clients, customers (if such
customers were customers of the Company within the year prior to the Closing
Date) or accounts of Seller or the Company, or Buyer (after the Closing Date),
related to the HCIS Business; or (ii) entice, induce or in any manner influence
any person who is in the employ or service of the Company prior to the Closing
Date to become employed by Seller or any other Person (provided, however, that
the Parties acknowledge and agree that Seller shall not be liable for a breach
of this Section 7.4.1(ii) for responses by such employees to general
solicitations for employment by Seller, or in the event such employees initiate
contact with the Seller);

                    7.4.2     Seller will not at any time disclose to any
person, other than Buyer or any of Buyer's Affiliates, or use any Trade Secrets
owned, possessed, licensed or used by or relating to the Company, whether or not
such information is embodied in writing or other physical form;


                                       29


                    7.4.3     Seller recognizes that all documents and objects
containing any Trade Secrets, whether developed by Seller or the Company or by
someone else for Seller or any of its Affiliates, will after the Closing Date
become the respective exclusive property of Buyer or any of its Affiliates, as
the case may be;

                    7.4.4     Because the breach or anticipated breach of the
restrictive covenant provided for in this Section 7.4 will result in immediate
and irreparable harm and injury to Buyer and its Affiliates, for which they will
not have an adequate remedy at law, Seller agrees that Buyer and its Affiliates
shall be entitled to relief in equity to temporarily and/or permanently enjoin
such breach or anticipated breach and to seek any and all other legal and
equitable remedies to which Buyer and its Affiliates may be entitled. It is
expressly understood and agreed that although Seller and Buyer consider the
restrictions contained in this Section 7.4 to be reasonable and necessary to
protect the Business in the context in which made, if a final judicial
determination is made that the time, territory, scope or any other restriction
contained in this Section 7.4 is unreasonable or otherwise unenforceable,
neither this Agreement nor the provisions of this Section 7.4 shall be rendered
void, but shall be deemed amended to apply as to such maximum scope, time and
territory and to such other extent as such court may judicially determine or
indicate to be reasonable, or if such court does not so determine or indicate,
to the maximum extent which any pertinent statute or judicial decision may
indicate to be a reasonable restriction under the circumstances involved, and as
so modified, the restrictions contained in this Section 7.4 shall be binding and
enforceable; and

                    7.4.5     Notwithstanding anything to the contrary contained
in this Section 7.4, Buyer acknowledges and agrees that Seller shall not be in
breach of this covenant not to compete in the event that Seller, during the
period set forth herein, is acquired by a third party pursuant to a Change of
Control Acquisition (as defined below) which such third party's business
includes HCIS Business. For purposes of this Section 7.4.5, a "Change of Control
Acquisition" shall mean the merger or consolidation of Seller with or into
another corporation or entity, or the merger or consolidation of any other
corporation or entity with or into the Seller, pursuant to which the
shareholders of Seller immediately prior to such merger or consolidation hold
less than 50% of the voting equity securities of the surviving corporation or
entity immediately after such transaction.

                    7.4.6     Notwithstanding anything to the contrary contained
in this Section 7.4, no provision of this Section 7.4 shall in any way limit
Seller's ability to design, develop or provide, alone or in combination with
other parties, image management, workflow engines or PACS products or solutions
if sold as a feature of, enhancement to, or extension of Seller's products after
the Closing Date. It is understood and agreed that Seller may provide such
features, enhancements or extensions in connection with its Nuclear Medicine,
PET and Radiation Therapy products, as well as any other clinical devices it may
develop in the future (other than related to the HCIS Business).

          7.5       CARDIOLOGY SYSTEMS GROUP. Prior to the Closing, the Company
shall transfer to the Seller, or an Affiliate of Seller, or a third party
purchaser, all of the assets and liabilities of the Cardiology Systems Group.
After the Closing, Buyer and the Company shall use all commercially reasonable
efforts to take all actions and to do all things necessary or advisable to
consummate such transfer of the assets and assumption of liabilities of the
Cardiology Systems

                                       30


Group, including without limitation (i) working with any purchaser of such
business with respect to shared clients and customers and coordinating marketing
and billing issues, and (ii) the transfer of the Marks "CorCATT" and "CorTET" to
the third party purchaser, as well as the Copyrights identified on SCHEDULE
3.17.6 to such purchaser. Unless required for consummation of such transfer of
the Cardiology Systems Group, Buyer and the Company shall have no obligation to
amend, or cause to be amended, any Contract, to change, or cause to be changed,
any Permit, or to make, or cause to be made, any payment to obtain any Consent;
provided, however, that Buyer and the Company shall not be required to incur
unreasonable expense. Seller shall work in good faith to obtain a similar
commitment from the purchaser of the Cardiology Systems Group to use
commercially reasonable efforts to take all actions and to do all things
necessary or advisable to consummate the transfer of the assets and assumption
of liabilities of the Cardiology Systems Group to such purchaser, including
working with the Company with respect to shared clients and customers and
coordinating marketing and billing issues.

          7.6       HSR ACT. As soon as may be reasonably practicable, to the
extent applicable, the Seller, Company and Buyer each shall file, with the FTC
and the Antitrust Division of the DOJ, Notification and Report Forms relating to
the transaction contemplated herein as required by the HSR Act, as well as
comparable pre-merger notification forms required by the merger notification or
control laws and regulations of any applicable jurisdiction, as agreed to by the
Parties. The Buyer and Seller each shall promptly (i) supply the others with any
information which may be required in order to effectuate such filings, and (ii)
supply any additional information which reasonably may be required by the FTC,
the DOJ or the competition or merger control authorities of any other
jurisdiction and which the Parties may reasonably deem appropriate. Any and all
costs associated with such filings shall be shared equally between Buyer and
Seller.

          7.7       HOUSTON LEASE. The Parties acknowledge that in order to
obtain the consent of the landlord (the "Houston Landlord") to the assignment to
the Surviving Corporation of the lease regarding the Company's leased facility
at Five Greenway Plaza, Suite 1900, Houston, TX (the "Houston Lease"), the
Houston Landlord may require the renegotiation of various aspects of such Lease,
including the rental payments. Prior to the Closing Date, the Parties shall
discuss in good faith whether the Houston Lease contains leased space not
reasonably required by Buyer for the ongoing operations of the Surviving
Corporation after the Closing, as well as the costs involved with decreasing the
amount of space needed by the Surviving Corporation, including but not limited
to moving to and reconfiguring the remaining space. To the extent the Houston
Landlord has demanded an increase in rent or any other costs associated with the
Houston Lease, the Parties agree to negotiate in good faith to reduce the
economic impact to the Surviving Corporation of any such Landlord demand,
including considering reducing the amount of space under the Houston Lease after
the Closing Date; provided, however, that the final decision to reduce the
amount of space under the Houston Lease shall be made by Buyer based upon its
reasonably anticipated ongoing business requirements for the Company. In
addition, to the extent necessary, the Parties shall further negotiate in good
faith reasonable accommodations in order to allow Buyer to agree to conditions
imposed by the Houston Landlord as a condition of such Landlord's consent to the
assignment of the Houston Lease.


                                       31


                                    ARTICLE 8
                         CONDITIONS PRECEDENT TO CLOSING

          8.1       CONDITIONS PRECEDENT TO BUYER'S OBLIGATIONS. The obligation
of Buyer to consummate the transactions contemplated by this Agreement shall be
subject to the satisfaction of the following conditions, any of which may be
waived in writing by Buyer:

                    8.1.1     ACCURACY OF REPRESENTATIONS AND WARRANTIES. The
representations and warranties of Seller in this Agreement that are qualified as
to materiality shall be accurate, and any such representations and warranties
that are not so qualified shall be accurate in all material respects as of the
date of this Agreement and as of the Closing Date (except for representations
and warranties that address matters only as of a specific date, in which case
such representations and warranties qualified as to materiality shall be true
and correct, and those not so qualified shall be true and correct in all
material respects, on and as of such specific date).

                    8.1.2     PERFORMANCE OF COVENANTS. Seller and the Company
shall have performed and complied in all material respects with all covenants
and agreements required by this Agreement to be performed by Seller and the
Company prior to or at the Closing.

                    8.1.3     DELIVERY OF DOCUMENTS. Seller shall have delivered
to Buyer the documents required by Section 2.2.2.

                    8.1.4     NO ORDER. No Order shall be in effect forbidding
or enjoining the consummation of the transactions contemplated hereby.

                    8.1.5     REQUIRED CONSENTS. Seller or the Company shall
have obtained all Required Consents to the consummation of the transactions
contemplated by this Agreement.

                    8.1.6     RESERVED.

                    8.1.7     KEY EMPLOYEES. Each Key Employee shall be employed
by the Company as of the Closing Date and, to Seller's Knowledge, shall not have
provided the Company or Seller with notice of his or her intention to terminate
employment with the Company after the Closing Date; provided, however, that this
Section 8.1.7 shall not apply to the Chief Operating Officer of the Company.

                    8.1.8     TERMINATION OF GUARANTY. Seller or the Company
shall have terminated the subsidiary guaranty and all related agreements with
ABN Amro and any liens granted by the Company pursuant to such guaranty and all
related agreements shall have been released.

                    8.1.9     CARDIOLOGY SYSTEMS GROUP. Seller shall have
transferred the assets and liabilities of the Cardiology Systems Group to a
third party purchaser or to Seller (or any Affiliate thereof).

                    8.1.10    ARTICLES AND CERTIFICATE OF MERGER. The Articles
of Merger and Certificate of Merger shall have been filed with, and accepted by,
the Secretary of State of the State of Texas and Delaware, respectively.



                                       32


                    8.1.11    SERVICES AGREEMENT. Buyer and Seller shall have
negotiated in good faith, executed and delivered a Services Agreement between
such Parties providing for, among other things, the matters set forth on
SCHEDULE 8.1.11.

                    8.1.12    HSR ACT. All waiting periods, if any, under the
HSR Act relating to the transactions contemplated hereby shall have expired or
terminated early.

                    8.1.13    AUDITED BASELINE BALANCE SHEET. Seller shall have
delivered to Buyer an Audited Baseline Balance Sheet and there shall not have
been a material adverse difference between the unaudited Baseline Balance Sheet
(included as part of SCHEDULE 3.7.1) and the Audited Baseline Balance Sheet;
provided, however, that if there is such a difference and Buyer does not waive
this condition in writing, Buyer and Seller shall negotiate in good faith to
agree on an amendment to this Agreement that shall make an appropriate
adjustment to the Purchase Price.

          8.2       CONDITIONS PRECEDENT TO SELLER'S OBLIGATIONS. The obligation
of Seller to consummate the transactions contemplated by this Agreement shall be
subject to the satisfaction of the following conditions, any of which may be
waived in writing by Seller.

                    8.2.1     ACCURACY OF REPRESENTATIONS AND WARRANTIES. The
representations and warranties of Buyer in this Agreement that are qualified as
to materiality shall be accurate, and any such representations and warranties
that are not so qualified shall be accurate, in all material respects, as of the
date of this Agreement and as of the Closing Date (except for representations
and warranties that address matters only as of a specific date, in which case
such representations and warranties qualified as to materiality shall be true
and correct, and those not so qualified shall be true and correct in all
material respects, on and as of such earlier date).

                    8.2.2     PERFORMANCE OF COVENANTS. Buyer shall have
performed and complied in all material respects with all covenants and
agreements required by this Agreement to be performed by Buyer prior to or at
the Closing.

                    8.2.3     DELIVERIES. Buyer shall have delivered to Seller
the payments and documents required by Section 2.2.3.

                    8.2.4     NO ORDER. No Order shall be in effect forbidding
or enjoining the consummation of the transactions contemplated hereby.

                    8.2.5     338(h)(10) ELECTION. Seller shall have received
the completed Section 338(h)(10) Election from Buyer, as contemplated under
Section 2.12 above.

                    8.2.6     ARTICLES AND CERTIFICATE OF MERGER. The Articles
of Merger and Certificate of Merger shall have been filed with, and accepted by,
the Secretary of State of the State of Texas and Delaware, respectively.

                    8.2.7     SERVICES AGREEMENT. Buyer and Seller shall have
negotiated in good faith, executed and delivered a Services Agreement between
such Parties providing for, among other things, the matters set forth on
SCHEDULE 8.1.11.


                                       33


                    8.2.8     HSR ACT. All waiting periods, if any, under the
HSR Act relating to the transactions contemplated hereby shall have expired or
terminated early.

                                    ARTICLE 9
                        TERMINATION PRIOR TO CLOSING DATE

          9.1       TERMINATION. This Agreement may be terminated prior to the
Closing Date only as follows:

                    9.1.1     by either Buyer or Seller upon written notice to
the other Party if a material Breach of any provision of this Agreement has been
committed by the other Party and such breach has not been waived in writing;

                    9.1.2     by the mutual written consent of the Buyer and
Seller; or

                    9.1.3     by either Buyer or Seller upon written notice if
the Closing has not occurred on or prior to November 30, 2000.

          9.2       EFFECT OF TERMINATION. If this Agreement terminates pursuant
to Section 9.1, no Party shall have any liability or obligation to the other
Party hereunder; provided, however, that no such termination shall relieve any
Party of any liability or Damages resulting from a willful breach of this
Agreement and Buyer shall be entitled to injunctive relief, specific performance
or other equitable relief (without the posting of any bond), for any breach of
this Agreement by Seller prior to the Closing; and provided further, however,
that the provisions of Article 12, this Section 9.2 and Section 2.3 above
(without Sections 2.3.1 and 2.3.2 thereunder) shall remain in full force and
effect and survive any termination of this Agreement.

                                   ARTICLE 10
                                 INDEMNIFICATION

          10.1      INDEMNIFICATION BY SELLER. Subject to the other provisions
of this Article 10, from and after the Closing Date, Seller shall indemnify and
hold Buyer, the Company, their Affiliates and their respective employees,
officers, directors and agents (the "Buyer Indemnitees") harmless from and
against any and all Damages suffered by any Buyer Indemnitee arising out of:

                    10.1.1    the breach of any representation or warranty made
by Seller in this Agreement or in any certificate required to be executed and
delivered by Seller, the Company or their respective officers at the Closing
pursuant to this Agreement;

                    10.1.2    the failure of Seller to perform any covenant or
obligation by Seller contained in this Agreement or any other agreement required
to be executed and delivered by Seller at the Closing pursuant to this
Agreement;

                    10.1.3    any and all Claims relating to any Liabilities of
the Company resulting from the Mandell or Evans employee litigation (the
"Current Employee Claims"), as disclosed on SCHEDULE 3.14; and



                                       34


                    10.1.4    the Cardiology Systems Group and its operations,
including the sale of Cardiology Systems Group products and claims by any
clients or customers of the Cardiology Systems Group, or any employees primarily
employed by the Cardiology Systems Group;

provided, however, that no Buyer Indemnitees shall be entitled to any such
indemnification pursuant to this Section 10.1 until such Indemnitees incur
Damages in excess of $200,000 (the "Basket Amount") in the aggregate, in which
case the Buyer Indemnitees shall be entitled to recover all Damages, up to the
Indemnity Cap (as defined below), including the Basket Amount; and provided
further, however, that such Basket Amount shall not apply to breaches of
covenants or obligations by Seller or to Damages relating to Sections 10.1.3 and
10.1.4.

          10.2      INDEMNIFICATION BY BUYER. Subject to the other provisions of
this Article 10, from and after the Closing Date, Buyer shall indemnify and hold
Seller, its Affiliates and their respective employees, officers, directors and
agents (the "Seller Indemnitees") harmless from and against any Damages suffered
by any Seller Indemnitee arising out of:

                    10.2.1    the breach of any representation or warranty made
by Buyer in this Agreement or in any certificate required to be executed and
delivered by Buyer or Merger Sub or their officers at the Closing pursuant to
this Agreement;

                    10.2.2    the failure of Buyer to perform any covenant or
obligation by Buyer contained in this Agreement or any other agreement required
to be executed and delivered by Buyer at the Closing pursuant to this Agreement;
and

                    10.2.3    any Damages resulting to Seller due to any Claim
by an Employee against the Buyer after the Closing, pursuant to which Seller is
named a party in its capacity as the former sole shareholder of the Company,
unless such Claim arises due to a breach by Seller of its representation and
warranty under Section 3.14 above;

provided, however, that no Seller Indemnitees shall be entitled to any such
indemnification pursuant to this Section 10.2 until such Indemnitees incur
Damages in excess of the Basket Amount in the aggregate, in which case the
Seller Indemnitees shall be entitled to recover all Damages, up to the Indemnity
Cap (as defined below), including the Basket Amount; and provided further,
however, that such Basket Amount shall not apply to breaches of covenants or
obligations by Buyer.

          10.3      NOTICE AND RESOLUTION OF CLAIMS.

                    10.3.1    NOTICE. Each person entitled to indemnification
pursuant to Section 10.1 or Section 10.2 (an "Indemnitee") shall promptly give
written notice to the indemnifying Party after obtaining knowledge of any claim
that it may have pursuant to this Article 10. Such notice shall set forth in
reasonable detail the claim and the basis for indemnification.

                    10.3.2    RIGHT TO ASSUME DEFENSE. If such claim for
indemnity shall arise from a claim or Action involving a third party (a "Third
Party Claim"), the Indemnitee shall permit the indemnifying Party (the
"Indemnifying Party") to assume its defense. If the Indemnifying Party assumes
the defense of such Third Party Claim, it shall take all steps, as advised by
its counsel,



                                       35


necessary to investigate, defend or settle such Action and shall, subject to
Section 10.4 below, hold the Indemnitee harmless from and against any and all
Damages caused by or arising out of any settlement approved by the Indemnifying
Party or any judgment in connection with such Third Party Claim. Without the
written consent of the Indemnitee, the Indemnifying Party shall not consent to
entry of any judgment or enter into any settlement that does not include an
unconditional and complete release of the Indemnitee by the claimant or
plaintiff making the Third Party Claim without the imposition of any injunction
or other equitable relief against the Indemnitee. The Indemnitee may participate
in such defense or settlement through its own counsel, but at its own expense;
provided, however, that if there is an actual conflict of interest between
Indemnitee and the Indemnifying Party with respect to such Third Party Claim,
which shall be subject to the reasonable determination of the Indemnitee and
subject to the reasonable approval of the Indemnifying Party, the Indemnitee may
retain its own counsel at the Indemnifying Party's expense.

                    10.3.3    FAILURE TO ASSUME DEFENSE. Failure by the
Indemnifying Party to notify the Indemnitee of its election to assume the
defense of any Third Party Claim within 30 calendar days after its receipt of
notice thereof pursuant to Section 10.3.1 shall be deemed a waiver by the
Indemnifying Party of its right to assume the defense of such Third Party Claim.
In such event, the Indemnitee may defend against such Third Party Claim in any
manner it deems appropriate. The Indemnitee may settle such Third Party Claim,
or consent to the entry of any judgment with respect thereto, provided that it
acts in good faith and in a commercially reasonable manner.

          10.4      SURVIVAL. Neither Party shall have any obligation to
indemnify any Indemnitee pursuant to Sections 10.1.1 or 10.2.1 for the breach of
any representation or warranty unless such Indemnitee has given written notice
to such Party of such breach in accordance with Section 10.3.1 prior to the
expiration of two years after the Closing Date, in the case of all
representations and warranties except:

                              (i)       those representations and warranties set
forth in Section 3.15 in respect of which such notice must be given prior to the
fifth anniversary of the Closing Date;

                              (ii)      those representations and warranties set
forth in Section 3.4, Section 3.5 or Section 4.2 which shall survive
indefinitely; and

                              (iii)     those representations and warranties set
forth in Sections 3.19 and 3.20 which shall survive until the expiration of the
statutory limitation periods pertaining to the respective events which may
constitute a breach of such representations and warranties.

          10.5      MAXIMUM PAYMENTS; EXCLUSIVE REMEDY. The maximum obligation
for Damages by either Party pursuant to this Article 10 shall not exceed
$4,000,000 (the "Indemnity Cap"); provided, however, that the Indemnity Cap
shall not apply to Damages incurred by the Buyer (i) related to the Current
Employee Claims, (ii) pursuant to Section 10.1.4 above, and (iii) due to
Seller's breaches of its representations and warranties contained in Sections
3.15 and 3.20. In addition, the rights of the Parties under this Article 10
shall be the exclusive remedy for breaches of representations and warranties or
breaches of covenants of the Parties under this Agreement, or, in the case of
the Buyer only, for Damages resulting to the Buyer or the Company under Sections
10.1.3 or 10.1.4 above, except for (i) any such breaches resulting due to



                                       36


fraud by a Party, or (ii) in the case of Buyer only, Buyer's ability to seek
specific performance, or other equitable relief, due to any breaches by Seller
of its covenants and obligations pursuant to Sections 5.8, 7.2, 7.3, 7.4, 7.5
and Article 11. Any obligation under this Article 10 of Seller to Buyer or the
Company may be offset against the Buyer's payment obligations under Sections
2.10.2 or 2.10.3.

          10.6      OTHER INDEMNITEES. Buyer shall cause Buyer Indemnitees, and
Seller shall cause Seller Indemnitees, to comply with the provisions and to
abide by the limitations set forth in this Article 10.

                                   ARTICLE 11
                                EMPLOYEE MATTERS

          11.1      RESERVED.

          11.2      CHIEF OPERATING OFFICER. Prior to the Closing Date, Buyer
shall decide whether or not it desires to employ the Chief Operating Officer of
the Company. If Buyer determines it wishes to employ such Officer, it shall make
an offer to such Officer which such offer, by its terms, shall require
acceptance prior to the Closing Date. If such Officer accepts Buyer's offer of
employment as of the Closing Date, Buyer shall thereafter be responsible for all
benefits, severance and other customary employee payment obligations for such
Officer. If Buyer determines not to employ the Chief Operating Officer of the
Company, or such Officer does not accept Buyer's offer of employment prior to
the Closing Date, Buyer shall provide Seller with written notice to such effect
and Seller shall be responsible for all benefits, severance and other customary
employee payment obligations for such Officer; provided, however, that Seller
shall make such Officer reasonably available to Buyer and the Company (if such
Officer remains employed by Seller) on a part-time basis, not to exceed 50% of
such Officer's time, for a period not to exceed 90 calendar days after the
Closing Date. Buyer shall reimburse Seller for such Officer's time (as to be
provided in the Services Agreement).

          11.3      STOCK OPTIONS. As soon as practicable after the date of this
Agreement, Seller shall provide notice to the option holders under the Company
Option Plan that Buyer will not be assuming the options outstanding under such
Plan. In the event that any optionee exercises its option (as such optionee
shall have the ability to do for the requisite period under the Company Option
Plan or otherwise) to purchase Common Stock of the Company, the Parties agree
that they shall amend this Agreement as necessary to provide that such optionees
are entitled to receive their pro rata portion of the Purchase Price, as well as
any other required amendments pursuant thereto.

          11.4      CONTINUED COVERAGE UNDER PLANS. From and after the Closing
Date, Buyer shall be responsible for all payroll services for Employees. Seller
shall make arrangements for prompt payment of any payroll or other benefits to
Employees due as of the Closing Date. Seller shall not be responsible for any
such payments after the Closing Date. In addition, Seller will facilitate the
transition of the Employees to COBRA insurance coverage as of the Closing Date
and Buyer shall pay to Seller on behalf of all Employees the cost of such COBRA
coverage. Buyer agrees to transition any Employees to Buyer's health plans no
later than January 1, 2001. Seller shall not be responsible for any other
employee benefits or plans as of the Closing Date;


                                       37


provided, however, that Seller shall use its best efforts to facilitate the
transfer of any such employee benefits or plans of the Company to Buyer after
the Closing Date. In addition, Buyer shall assume the accrued vacation liability
of the Employees as of the Closing Date and Seller shall have no responsibility
for such accrued vacation liability thereafter.

                                   ARTICLE 12
                                  MISCELLANEOUS

          12.1      SEVERABILITY. If any provision of this Agreement as applied
to any party or to any circumstance shall be held invalid, illegal or
unenforceable by any court of competent jurisdiction, (i) the validity, legality
and enforceability of the remaining provisions of this Agreement will remain in
full force and effect, and (ii) the application of such provision to any other
part or to any other circumstance shall not be affected or impaired thereby.

          12.2      SUCCESSORS AND ASSIGNS. The terms and conditions of this
Agreement shall inure to the benefit of, and be binding upon, the successors,
whether by merger, consolidation or otherwise, and permitted assigns of the
parties; provided, however, that neither this Agreement nor any of the rights or
obligations hereunder may be assigned by any party without the prior written
consent of the other party. Any assignment in violation of this Section 12.2
shall be null and void.

          12.3      COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall for all purposes be deemed to be an original
and all of which, when taken together, shall constitute one and the same
agreement.

          12.4      HEADINGS. The captions and headings used in this Agreement
are inserted for convenience only and shall not be deemed to constitute part of
this Agreement or to affect the construction or interpretation hereof.

          12.5      WAIVER. Any of the terms or conditions of this Agreement may
be waived in writing at any time by the party which is entitled to the benefits
thereof. Neither the failure nor any delay by any party in exercising any right,
power or privilege under this Agreement, or the documents referred to in this
Agreement, will operate as a waiver of such right, power or privilege, and no
single or partial exercise of any such right, power or privilege will preclude
any other or further exercise of such right, power or privilege or the exercise
of any other right, power or privilege.

          12.6      NO THIRD-PARTY BENEFICIARIES. Nothing in this Agreement
shall create or confer upon any Person (including but not limited to any
Employees), other than the parties or their respective successors and permitted
assigns, any legal or equitable rights, remedies, obligations, liabilities or
claims under or with respect to this Agreement, except as expressly provided
herein.

          12.7      NOTICES. Unless otherwise provided, all notices and other
communications hereunder shall be in writing and shall be deemed duly given (i)
on the date of delivery if delivered personally, or by telecopy or
telefacsimile, upon confirmation of receipt, in each case, if on a Business Day,
and otherwise on the next Business Day, (ii) on the fifth Business Day following
the date of mailing if delivered by registered or certified mail, return receipt
requested, postage prepaid, or (iii) the second Business Day if delivered by
nationally recognized overnight



                                       38


courier. All notices hereunder shall be delivered as set forth below, or
pursuant to such other instructions as may be designated in writing by the party
to receive such notice:

                  If to Seller or the Company (prior to Closing):

                           ADAC Laboratories
                           540 Alder Drive
                           Milpitas, CA 95035
                           Attention: Chairman and Chief Executive Officer
                           Telephone: (408) 321-9100
                           Facsimile: (408) 321-9686

                           with a copy to:

                           Wilson Sonsini Goodrich & Rosati
                           650 Page Mill Road
                           Palo Alto, CA  94304
                           Attention: Page Mailliard, Esq.
                           Telephone: (650) 493-9300
                           Facsimile: (650) 493-6811

                  If to Buyer, Merger Sub or the Company (after the Closing):

                           Cerner Corporation
                           2800 Rockcreek Parkway
                           Kansas City, Missouri 64117
                           Attention: President
                           Telephone: (816) 221-1024
                           Facsimile: (816) 474-1742

                           with copies to:

                           Cerner Corporation
                           2800 Rockcreek Parkway
                           Kansas City, Missouri 64117
                           Attention: General Counsel
                           Telephone: (816) 201-2556
                           Facsimile: (816) 201-8556

                           Stinson, Mag & Fizzell, P.C.
                           1201 Walnut Street, Suite 2800
                           Kansas City, MO 64106
                           Attention: Craig L. Evans
                           Telephone: (816) 842-8600
                           Facsimile: (816) 691-3495



                                       39


          12.8      GOVERNING LAW. This Agreement shall be construed in
accordance with and governed by the Laws of the State of Delaware applicable to
agreements made and to be performed wholly within such jurisdiction, without
regard to conflicts of law principles.

          12.9      INTERPRETATION.

                    12.9.1    Unless specifically stated otherwise, references
to Articles, Sections, Exhibits and Schedules refer to Articles, Sections,
Exhibits and Schedules in this Agreement. References to "includes" and
"including" mean "includes without limitation" and "including without
limitation."

                    12.9.2    No provision of this Agreement shall be
interpreted in favor of, or against, either of the parties by reason of the
extent to which either such party or its counsel participated in the drafting
thereof or by reason of the extent to which any such provision is inconsistent
with any prior draft hereof or thereof.

          12.10     PUBLIC ANNOUNCEMENTS. Seller and Buyer shall agree on the
terms of any press releases or other public announcements related to this
Agreement and shall consult with each other before issuing any press releases or
other public announcements related to this Agreement. In addition, the parties
agree to consult with, and provide commercially reasonable cooperation to, each
other with respect to the form and content of any communication to Employees,
customers, suppliers and others having dealings with the Company concerning this
Agreement and the transactions contemplated thereby through the Closing Date.

          12.11     ENTIRE AGREEMENT. This Agreement, together with the
Schedules and Exhibits hereto, constitutes the sole understanding of the parties
with respect to the matters contemplated hereby and thereby and supersedes and
renders null and void all prior agreements and understandings, written and oral,
between the parties with respect to the subject matter hereof and thereof. No
party shall be liable or bound to any other party in any manner by any promises,
conditions, representations, warranties, covenants, agreements and
understandings, except as specifically set forth herein or therein.

          12.12     AMENDMENT. No amendment, modification or alteration of the
terms or provisions of this Agreement, including any Schedules and Exhibits,
shall be binding unless the same shall be in writing and duly executed by the
party against whom such amendment, modification or alteration is sought to be
enforced.

          12.13     CONFIDENTIALITY. The parties acknowledge that the
Confidentiality and Non-Disclosure Agreement dated October 4, 2000 remains in
full force and effect and shall continue in full force and effect upon any
termination of this Agreement pursuant to Article 9 above.


                                       40


          IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed as of the date set forth above.

                                            CERNER CORPORATION


                                            By:
                                               -------------------------------
                                                     Name:
                                                          --------------------
                                                     Title:
                                                           -------------------


                                            CERNER RIS ACQUISITION CORPORATION

                                            By:
                                               -------------------------------
                                                     Name:
                                                          --------------------
                                                     Title:
                                                           -------------------

                                            ADAC LABORATORIES

                                            By:
                                               -------------------------------
                                                     Name:
                                                          --------------------
                                                     Title:
                                                           -------------------

                                            ADAC HEALTHCARE INFORMATION
                                            SYSTEMS, INC.

                                            By:
                                               -------------------------------
                                                     Name:
                                                          --------------------
                                                     Title:
                                                           -------------------



                                        EXHIBITS

         EXHIBIT A(1)              Articles of Merger

         EXHIBIT A(2)              Agreement of Merger

         EXHIBIT B(1)              Secretary's Certificate of Seller

         EXHIBIT B(2)              Secretary's Certificate of the Company

         EXHIBIT B(3)              Secretary's Certificate of Buyer

         EXHIBIT B(4)              Secretary's Certificate of Merger Sub

         EXHIBIT C(1)              Officer's Certificate of Seller

         EXHIBIT C(2)              Officer's Certificate of Buyer

         EXHIBIT D(1)              Form of Opinion of Counsel to Seller

         EXHIBIT D(2)              Form of Opinion of Counsel to Buyer

EX-99.1

                                                                    EXHIBIT 99.1

CERNER CORPORATION AGREES TO ACQUIRE ADAC'S HEALTH CARE INFORMATION SYSTEMS
BUSINESS

KANSAS CITY, Mo. & MILPITAS, Calif.--(BW HealthWire)--Oct. 24, 2000--Cerner
Corporation and ADAC Laboratories today announced that Cerner has agreed to
acquire ADAC's Health Care Information Systems (HCIS) business, excluding its
Cardiology Systems Group, for approximately $6 million cash.

The companies expect to complete the transaction in November 2000, pending
customary closing conditions and regulatory approval.

Cerner Corporation designs, develops, markets, installs and supports
information systems and content solutions for health organizations and
consumers. Cerner's HNA Millennium-Registered Trademark- suite of clinical,
management, and financial information systems is the most innovative and
integrated HIS package to span the continuum of care and deliver significant
benefits to healthcare organizations in terms of increased quality of care,
patient safety and operational efficiencies.

"ADAC's HCIS business, which produces information and image management solutions
for radiology departments, will provide a unique complement to our significant
radiology client base," said Neal L. Patterson, Chairman and chief executive
officer of Cerner. "Radiology is one of the most important diagnostic centers of
healthcare. The acquisition of ADAC's HCIS business will allow Cerner to broaden
our market presence in the radiology industry. A broad installed base of
clinical systems furthers our mission to increase healthcare efficiencies,
reduce medical error and improve appropriate clinical decision-making. We are
pleased to acquire the tremendous radiology capabilities of ADAC's HCIS and look
forward to meeting the evolving needs of its client base." "Cerner is proud of
our record of product innovation, combined with one of the highest levels of
client satisfaction and support in the healthcare technology industry,"
continued Mr. Patterson. "We look forward to serving the future needs of ADAC's
HCIS clients and sharing Cerner's vision for transforming health care with these
new clients. We believe this transaction will be non-dilutive financially in
2001 and will contribute positively to earnings in 2002."

R. Andrew Eckert, ADAC's chief executive officer, said, "We are pleased to
announce this agreement that we expect will be beneficial for all parties
involved. We believe that ADAC's HCIS customers will be well served by Cerner,
the leading provider of information technology in the health care industry. For
ADAC, this transaction will enable us to fully concentrate our resources on our
core businesses of nuclear medicine, positron emission tomography, and radiation
therapy products."

ADAC anticipates that it will take a charge of approximately $7 million (net of
tax) in its fourth fiscal quarter ended October 2, 2000, as a result of the
divestiture. This is in addition to the company's previously announced $2
million charge relating to the disposition of the Cardiology Systems Group,
which ADAC is selling to Camtronics, a subsidiary of Analogic Corporation. ADAC
expects to treat the HCIS business as a discontinued operation and to report an
estimated loss for the fourth quarter of approximately $.05 per share for HCIS,
separately from the results of its continuing operations.

About Cerner Corporation

Cerner Corporation (WWW.CERNER.COM) is the leading supplier of
clinical and management information and knowledge systems to more than 1,000
healthcare organizations worldwide. Cerner's mission is to connect the
appropriate persons, knowledge, and resources at the appropriate time and
location to achieve the optimal health outcome. The company's vision is to
improve the health of communities through innovation and investments in
information technology. Cerner strives to transform the healthcare delivery
system by increasing the quality of care, improving efficiencies, eliminating
medical error and connecting the individual to the system with innovative
information solutions. HNA Millennium is Cerner's comprehensive suite of
solutions that promote personal and community health management by connecting
consumers, clinicians and healthcare organizations into a streamlined, unified
single care process. HNA Millennium applications work on a cohesive platform
that is open, intelligent and scalable, allowing vital health




information to be accessed and shared throughout the healthcare system.
Cerner...we make healthcare smarter. Cerner and HNA Millennium are trademarks of
Cerner.

About ADAC Laboratories

ADAC Laboratories is the world market-share leader in nuclear medicine and
radiation therapy products, and an emerging leader in positron emission
tomography. ADAC is headquartered in Milpitas, CA. Additional information about
ADAC can be found on its web site at WWW.ADACLABS.COM.

This press release contains forward-looking statements within the meaning of the
Securities Act, including statements regarding the proposed acquisition of
ADAC's HCIS business by Cerner and the future benefits of this transaction.
Factors that could cause actual results to differ materially from those
contained in such forward-looking statements include, but are not limited to,
risks related to the planned acquisition including the inability to close the
planned transaction or to achieve expected synergies; the successful integration
and market acceptance of the product technologies; and other factors as
described in the "Business Considerations" section of ADAC's most recent Form
10-Q for the fiscal quarter ended July 2, 2000, and in Cerner's periodic filings
with the Securities and Exchange Commission. All forward-looking statements are
based on information available to the companies on the date hereof, and the
companies assume no obligation to update such statements.

CONTACT:
     Cerner
     Marc Naughton, 816/201-2525 (Investors)
     MNAUGHTON@CERNER.COM

     or
     Ashley Crosby Davidson, 816/201-1580 (Media)
     ACROSBY@CERNER.COM
     HTTP://WWW.CERNER.COM

     or
     ADAC Linda Snyder, 408/468-3750
     LSNYDER@ADACLABS.COM
     HTTP://WWW.ADACLABS.COM

EX-99.2

                                                                Exhibit 99.2

CERNER ACQUIRES ADAC HEALTHCARE INFORMATION SYSTEMS

KANSAS CITY, MO. - NOVEMBER 21, 2000 - Cerner is pleased to announce the
completion of its previously announced acquisition of ADAC Health Care
Information Systems (HCIS) from ADAC Laboratories for approximately $6
million in cash. ADAC HCIS produces information and image management
solutions for radiology departments. This acquisition is expected to be
non-dilutive in 2001 and is expected to contribute positively to earnings in
2002.

"There is significant synergy between ADAC HCIS and Cerner in terms of our
cultures, shared architectures and committment to radiology as one of the
most vital diagnostic centers of healthcare," said Neal L. Patterson, Cerner
chairman and chief executive officer. "This acquisition broadens our market
presence and enhances our knowledge capital in radiology. These additional
footprints within the radiology segment further Cerner's mission to make
healthcare smarter, safer and more efficient."

"In addition to the many clients of both ADAC HCIS and Cerner, we welcome
more than 125 new clients to Cerner and believe they will benefit from our
industry-leading client service, commitment to innovation and continued
support for QuadRIS-TM- and MARS-TM-," said Patterson. "These clients
represent some of the most prestigious and innovative healthcare
organizations in America. Cerner will deliver the much-anticipated QuadRIS
upgrade planned for spring 2001. While the functionality of QuadRIS and
Cerner's world-class radiology solution, RadNet-Registered Trademark-, will
merge over time, Cerner will provide a smooth technology and financial
upgrade path for these products."

"Clinical imaging is a critical component of the electronic medical record
and plays an increasing role in the diagnostic and therapeutic treatment of
patients," said Patterson. "In fact, the marketplace for PACS (picture
archiving and communications systems) image management solutions is growing
at three times the rate of the radiology information systems market. Cerner
will integrate specific, proven ADAC HCIS PACS technology from the Envol
suite of image management products into the HNA Millennium platform to
provide the most complete and integrated radiology offering in the world."

"The experience, knowledge and client service mentality of the staff at ADAC
HCIS complements Cerner's world-class team of radiology experts," said Trace
Devanny, president of Cerner. "We will maintain an office in Houston for
these new Cerner associates and look forward to merging our visions for
transforming healthcare through product innovation in radiology."

CERNER CORPORATION (NASDAQ: CERN, WWW.CERNER.COM) IS THE LEADING SUPPLIER OF
CLINICAL AND MANAGEMENT INFORMATION AND KNOWLEDGE SYSTEMS TO MORE THAN 1,200
HEALTHCARE ORGANIZATIONS WORLDWIDE. CERNER'S MISSION IS TO CONNECT THE
APPROPRIATE PERSONS, KNOWLEDGE, AND RESOURCES AT THE APPROPRIATE TIME AND
LOCATION TO ACHIEVE THE OPTIMAL HEALTH OUTCOME. THE COMPANY'S VISION IS TO
IMPROVE THE HEALTH OF COMMUNITIES THROUGH INNOVATION AND INVESTMENTS IN
INFORMATION TECHNOLOGY. CERNER STRIVES TO TRANSFORM THE HEALTHCARE DELIVERY
SYSTEM BY INCREASING THE QUALITY OF CARE, IMPROVING EFFICIENCIES, ELIMINATING
MEDICAL ERROR AND CONNECTING THE INDIVIDUAL TO THE SYSTEM WITH INNOVATIVE
INFORMATION SOLUTIONS. HNA MILLENNIUM IS CERNER'S COMPREHENSIVE SUITE OF
SOLUTIONS THAT PROMOTE PERSONAL AND COMMUNITY HEALTH MANAGEMENT BY CONNECTING
CONSUMERS, CLINICIANS AND HEALTHCARE ORGANIZATIONS INTO A STREAMLINED,
UNIFIED SINGLE CARE PROCESS. HNA MILLENNIUM APPLICATIONS WORK ON A COHESIVE
PLATFORM THAT IS OPEN, INTELLIGENT AND SCALABLE, ALLOWING VITAL HEALTH
INFORMATION TO BE ACCESSED AND SHARED THROUGHOUT THE HEALTHCARE SYSTEM.
CERNER ... WE MAKE HEALTHCARE SMARTER. THE FOLLOWING ARE TRADEMARKS OF CERNER
CORPORATION: CERNER, HNA MILLENNIUM, RADNET, QUADRIS, ENVOL AND MARS. THE
NAME ADAC HCIS HAS BEEN CHANGED TO CERNER RADIOLOGY INFORMATION SYSTEMS, INC.



CERNER ACQUIRES ADAC HEALTHCARE INFORMATION SYSTEMS           PAGE 2 OF 2


THIS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS THAT INVOLVE A NUMBER OF
RISKS AND UNCERTAINTIES. IT IS IMPORTANT TO NOTE THAT THE COMPANY'S
PERFORMANCE, FINANCIAL CONDITION OR BUSINESS COULD DIFFER MATERIALLY FROM
THOSE EXPRESSED IN SUCH FORWARD-LOOKING STATEMENTS. THE WORDS "WILL,"
"EXPECT" AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY SUCH
FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH
DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO: THE INABILITY TO ACHIEVE
EXPECTED SYNERGIES, THE SUCCESSFUL INTEGRATION AND MARKET ACCEPTANCE OF THE
PRODUCT TECHNOLOGIES, VARIATIONS IN THE COMPANY'S QUARTERLY OPERATING
RESULTS, VOLATILITY OF THE COMPANY'S STOCK PRICE, MARKET RISK OF INVESTMENTS,
CHANGES IN THE HEALTHCARE INDUSTRY, SIGNIFICANT COMPETITION, THE COMPANY'S
PROPRIETARY TECHNOLOGY MAY BE SUBJECTED TO INFRINGEMENT CLAIMS OR MAY BE
INFRINGED UPON, REGULATION OF THE COMPANY'S SOFTWARE BY THE U.S. FOOD AND
DRUG ADMINISTRATION OR OTHER GOVERNMENT REGULATION, THE POSSIBILITY OF
PRODUCT-RELATED LIABILITIES AND POSSIBLE FAILURES OR DEFECTS IN THE
PERFORMANCE OF THE COMPANY'S SOFTWARE. ADDITIONAL DISCUSSION OF THESE AND
OTHER FACTORS AFFECTING THE COMPANY'S BUSINESS IS CONTAINED IN THE COMPANY'S
PERIODIC FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. THE COMPANY
UNDERTAKES NO OBLIGATION TO UPDATE FORWARD-LOOKING STATEMENTS TO REFLECT
CHANGED ASSUMPTIONS, THE OCCURRENCE OF UNANTICIPATED EVENTS OR CHANGES IN
FUTURE OPERATING RESULTS, FINANCIAL CONDITION OR BUSINESS OVER TIME.